[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 112511
1. Cantarero Vallejo MD, Gómez Camarero J, Menchén L, Pajares Díaz JA, Lo Iacono O: [Liver damage and celiac disease]. Rev Esp Enferm Dig; 2007 Nov;99(11):648-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver damage and celiac disease].
  • In fact, a wide spectrum of liver injuries in children and adults may be related to CD, particularly: a) mild parenchymal damage characterized by absence of any clinical signs or symptoms suggesting chronic liver disease, and by non-specific histological changes reversible on a gluten-free diet;.
  • b) chronic liver damage with autoimmune etiology, including autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis, which may be associated with CD but are generally unaffected by gluten withdrawal; and c) severe liver failure and decompensated cryptogenetic liver cirrhosis, potentially treatable with a gluten-free diet.
  • Such different types of liver injuries may represent one same disorder where individual factors, such as genetic predisposition, precocity, and duration of exposure to gluten may influence reversibility of liver damage.
  • A rigorous cross-checking for asymptomatic liver damage in CD individuals and, conversely, for CD in any cryptogenic liver disorder, including end-stage liver failure, is recommended.
  • [MeSH-major] Celiac Disease / complications. Liver Diseases / complications

  • Genetic Alliance. consumer health - Celiac Disease.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271663.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 52
  •  go-up   go-down


2. Cui YJ, Aleksunes LM, Tanaka Y, Goedken MJ, Klaassen CD: Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol Sci; 2009 Jul;110(1):47-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice.
  • Farnesoid X receptor (FXR) and pregnane X receptor (PXR) are two major bile acid sensors in liver.
  • The purpose of this study was to characterize the regulation of hepatic transporters by FXR and PXR during ANIT-induced liver injury.
  • Livers from wild-type and PXR-null mice had comparable multifocal necrosis 48 h after ANIT.
  • However, ANIT-treated FXR-null mice have fewer and smaller necrotic foci than wild-type mice but had scattered single-cell hepatocyte necrosis throughout the liver.
  • Serum and liver unconjugated bile acids were higher in ANIT-treated FXR-null mice than the other two genotypes.
  • ANIT induced mRNA expression of Mdr2, Bsep, and Atp8b1 in wild-type and PXR-null mice but failed to upregulate these genes in FXR-null mice. mRNA expression of uptake transporters declined in livers of all genotypes following ANIT treatment.
  • ANIT increased Ostbeta and Mrp3 mRNA in livers of wild-type and PXR-null mice but did not alter Ostbeta mRNA in FXR-null mice.
  • In conclusion, FXR deficiency enhances susceptibility of mice to ANIT-induced liver injury, likely a result of impaired induction of hepatobiliary efflux transporters and subsequent hepatic accumulation of unconjugated bile acids.

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Baillieres Best Pract Res Clin Gastroenterol. 2000 Aug;14(4):571-83 [10976015.001]
  • [Cites] Dig Liver Dis. 2000 Mar;32(2):152-9 [10975791.001]
  • [Cites] Mol Pharmacol. 2001 Mar;59(3):627-35 [11179459.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3369-74 [11248085.001]
  • [Cites] Toxicology. 2001 Oct 5;167(1):73-81 [11557131.001]
  • [Cites] Hepatology. 2002 Mar;35(3):589-96 [11870371.001]
  • [Cites] Endocr Rev. 2002 Aug;23(4):443-63 [12202460.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1236-45 [12395335.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):633-71 [12663868.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):1037-42 [12671900.001]
  • [Cites] J Hepatol. 2003 Jun;38(6):717-27 [12763363.001]
  • [Cites] J Hepatol. 2003 Oct;39(4):480-8 [12971955.001]
  • [Cites] Annu Rev Biochem. 2003;72:137-74 [12543708.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1678-87 [14623915.001]
  • [Cites] Gastroenterology. 2004 Mar;126(3):756-64 [14988830.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):539-51 [15123373.001]
  • [Cites] Hum Mol Genet. 2004 Oct 15;13(20):2451-60 [15317749.001]
  • [Cites] Am J Med. 1971 Nov;51(5):568-79 [4399226.001]
  • [Cites] Gastroenterology. 1976 Aug;71(2):202-7 [939378.001]
  • [Cites] Pharmacol Rev. 1976 Sep;28(3):207-73 [16281.001]
  • [Cites] J Pharmacol Exp Ther. 1991 Jan;256(1):412-20 [1846424.001]
  • [Cites] Biochem Pharmacol. 1991 Nov 6;42(11):2171-80 [1958235.001]
  • [Cites] Cell. 1993 Nov 5;75(3):451-62 [8106172.001]
  • [Cites] J Hepatol. 1994 Aug;21(2):235-40 [7989715.001]
  • [Cites] Biochem Pharmacol. 1995 Oct 26;50(9):1469-74 [7503798.001]
  • [Cites] Hepatology. 1997 Jun;25(6):1539-42 [9185779.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):966-72 [9287990.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):10046-50 [9545351.001]
  • [Cites] Toxicol Sci. 2005 Jan;83(1):44-52 [15496496.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Feb;312(2):759-66 [15466244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2063-8 [15684063.001]
  • [Cites] Drug Metab Dispos. 2005 Jul;33(7):1062-73 [15843488.001]
  • [Cites] Drug Metab Dispos. 2005 Sep;33(9):1276-82 [15919853.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G798-805 [16002565.001]
  • [Cites] Hepatology. 2005 Dec;42(6):1270-9 [16317684.001]
  • [Cites] Hepatology. 2006 May;43(5):1013-21 [16628672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11323-8 [16844773.001]
  • [Cites] Drug Metab Dispos. 2006 Nov;34(11):1863-7 [16928788.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1768(3):637-47 [17141734.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Jul;45(1):96-105 [17592371.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):507-16 [17681172.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Oct 1;873(2):209-17 [18801708.001]
  • [Cites] Acta Gastroenterol Belg. 1999 Jul-Sep;62(3):300-5 [10547896.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2905-10 [10644759.001]
  • [Cites] Drug Metab Dispos. 2000 May;28(5):608-16 [10772642.001]
  • [Cites] Cell. 2000 Sep 15;102(6):731-44 [11030617.001]
  • (PMID = 19407337.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES009716; United States / NIEHS NIH HHS / ES / R01 ES013714; United States / NIEHS NIH HHS / ES / T32 ES007079; United States / NIEHS NIH HHS / ES / ES-009716; United States / NIEHS NIH HHS / ES / ES-009649; United States / NIEHS NIH HHS / ES / R01 ES009649; United States / NIEHS NIH HHS / ES / ES-007079; United States / NIEHS NIH HHS / ES / ES-013714
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers; 0 / Carrier Proteins; 0 / GW 4064; 0 / Isoxazoles; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / farnesoid X-activated receptor; 0 / pregnane X receptor; 551-06-4 / 1-Naphthylisothiocyanate; 63231-63-0 / RNA; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC2696329
  •  go-up   go-down


3. Increased liver regeneration rate and decreased liver function after synchronous liver and colon resection in rats. Ann Surg Innov Res; 2009 Dec 24;3:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased liver regeneration rate and decreased liver function after synchronous liver and colon resection in rats.
  • BACKGROUND: The surgical strategy for the treatment of colorectal cancer and synchronous liver metastases remains controversial.
  • The aim of the present study was to investigate the effects of colonic resection on liver function and regeneration in a rat model.
  • Group III and V had 40% or 70% of the liver resected, respectively.
  • Remnant liver function was evaluated by means of branched amino acids to tyrosine ratio.
  • Liver regeneration was calculated by (liver weight per 100 g of the body weight at sacrifice/preoperative projected liver weight per 100 g of the body weight) x 100.
  • Body weight and branched amino acids to tyrosine ratio were both significantly lower in rats that had simultaneous colonic and liver resection performed.
  • Hepatic regeneration rate was significantly higher in the simultaneous colectomy group.
  • CONCLUSIONS: In our model morbidity seems to be related to the extent of hepatic resection.
  • In rats undergoing liver resection, simultaneous colectomy induced a higher degree of hepatic regeneration rate.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem Biophys Methods. 1989 Mar;18(2):97-104 [2663963.001]
  • [Cites] Dev Immunol. 2002 Sep;9(3):143-9 [12885155.001]
  • [Cites] J Surg Res. 2001 Jan;95(1):54-60 [11120636.001]
  • [Cites] Am J Physiol. 1985 Nov;249(5 Pt 2):R551-62 [2865902.001]
  • [Cites] Eur Surg Res. 1995;27(6):396-405 [8542925.001]
  • [Cites] Scand J Gastroenterol. 1976;11(8):857-63 [794999.001]
  • [Cites] Hepatology. 1981 Sep-Oct;1(5):424-30 [7030905.001]
  • [Cites] Science. 1997 Apr 4;276(5309):60-6 [9082986.001]
  • [Cites] J Reticuloendothel Soc. 1982 Dec;32(6):409-22 [7161770.001]
  • [Cites] Surgery. 1987 Nov;102(5):846-51 [2823408.001]
  • [Cites] J Clin Lab Anal. 1999;13(1):31-4 [10025735.001]
  • [Cites] Eur J Clin Invest. 2008 Sep;38(9):640-8 [18837740.001]
  • [Cites] Surg Today. 1999;29(8):825-7 [10483769.001]
  • [Cites] Am Surg. 1992 Feb;58(2):88-91 [1550311.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1405-16 [10573519.001]
  • [Cites] Hepatogastroenterology. 2008 Mar-Apr;55(82-83):641-6 [18613424.001]
  • [Cites] Gastroenterology. 1977 Jun;72(6):1268-70 [858472.001]
  • [Cites] Eur Surg Res. 2007;39(1):17-22 [17164549.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Ann Surg. 1986 Feb;203(2):148-52 [3947153.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • (PMID = 20034379.001).
  • [ISSN] 1750-1164
  • [Journal-full-title] Annals of surgical innovation and research
  • [ISO-abbreviation] Ann Surg Innov Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806264
  •  go-up   go-down


Advertisement
4. Gruttadauria S, Vizzini G, Biondo D, Mandalà L, Volpes R, Palazzo U, Gridelli B: Critical use of extended criteria donor liver grafts in adult-to-adult whole liver transplantation: a single-center experience. Liver Transpl; 2008 Feb;14(2):220-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical use of extended criteria donor liver grafts in adult-to-adult whole liver transplantation: a single-center experience.
  • This study presents our experience with the use of extended criteria donor (ECD) liver grafts.
  • One hundred fifteen liver transplants were divided into 2 groups: standard (S) and nonstandard (NS).
  • Fifty-eight patients in group S received a liver procured from an ideal donor, whereas 57 patients in group NS received an organ from an ECD.
  • In the multivariate analysis, which was adjusted for recipient age and donor and recipient gender, hemodynamic risk factors and Model for End-Stage Liver.
  • Critical use of ECD liver grafts allowed recipients in the waiting list to have a greater chance of being transplanted.
  • [MeSH-major] Graft Rejection / etiology. Graft Survival. Liver Diseases / surgery. Liver Transplantation / methods. Living Donors. Patient Selection


5. Novais P, Robles-Medranda C, Pannain VL, Barbosa D, Biccas B, Fogaça H: Solitary fibrous liver tumor: is surgical approach the best option? J Gastrointestin Liver Dis; 2010 Mar;19(1):81-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous liver tumor: is surgical approach the best option?
  • Solitary fibrous tumor of the liver is a rare tumor, where the evolution, malignant potential, and invasive growth have not been well defined.
  • Although most cases are benign, there is no strict correlation between histological findings and biological behavior, and follow-up surveillance is necessary.
  • We present the case of a large solitary hepatic fibrous tumor and its clinical outcome after a 4-year follow-up.
  • The surgical resection is a plausible therapy in large solitary fibrous tumors of the liver, although liver transplantation may be discussed when the tumor is considered unresectable.
  • However, such aggressive approaches are questionable in asymptomatic patients due to the natural history of this tumor, which is not well known, and the risk of complications.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / surgery. Solitary Fibrous Tumors / surgery
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Liver Transplantation. Magnetic Resonance Imaging. Time Factors. Tomography, Spiral Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361081.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 15
  •  go-up   go-down


6. Vascotto C, Cesaratto L, D'Ambrosio C, Scaloni A, Avellini C, Paron I, Baccarani U, Adani GL, Tiribelli C, Quadrifoglio F, Tell G: Proteomic analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation. Proteomics; 2006 Jun;6(11):3455-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation.
  • Knowledge of early molecular events occurring upon ischemia/reperfusion (I/R) during liver transplantation (LT) is of great importance to improve the therapeutic intervention of surgical treatment.
  • To identify these proteins, we used a differential proteomics approach in the characterization human liver biopsies during I/R upon LT.
  • Analyses were performed on nine donor livers during LT.
  • By using 2-DE and MALDI-TOF MS, we identified 36 proteins which resulted significantly altered upon I/R injury.
  • Our data represent the first global approach in the study of I/R injury in liver.
  • [MeSH-major] Liver / chemistry. Liver Transplantation. Proteome / analysis. Reperfusion Injury / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622838.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Proteome
  •  go-up   go-down


7. Shen P, Geisinger KR, Zagoria R, Levine EA: Pathologic correlation study of microwave coagulation therapy for hepatic malignancies using a three-ring probe. J Gastrointest Surg; 2007 May;11(5):603-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic correlation study of microwave coagulation therapy for hepatic malignancies using a three-ring probe.
  • Microwave coagulation therapy (MCT) for the ablation of unresectable hepatic malignancies is a promising alternative to radiofrequency and cryoablation techniques.
  • In vivo pathologic evaluation of ablated tumor tissue is not well described for the three-ring microwave probe.
  • The study design was a prospective trial enrolling patients with resectable hepatic malignancies.
  • Lesions underwent in vivo MCT with the three-ring probe prior to liver resection.
  • Gross and histologic evaluations of the tumor were performed, including nicotinamide adenine dinucleotide (NADH) vital staining.
  • Fifty-six percent of the tumors demonstrated evidence of spontaneous coagulative necrosis on immediate histologic examination.
  • NADH vital staining was performed of the ablation zones with 100% absence of staining in the tumor tissue and in benign hepatic parenchyma, which is consistent with irreversible cellular damage.
  • In conclusion, in vivo MCT of hepatic malignancies with the three-ring probe produces nonviable tumor cells after a 5-min ablation.
  • [MeSH-major] Electrocoagulation / methods. Liver Neoplasms / surgery. Microwaves / therapeutic use
  • [MeSH-minor] Carcinoma / pathology. Carcinoma / secondary. Carcinoma / surgery. Cell Death. Colonic Neoplasms / pathology. Coloring Agents. Equipment Design. Hepatectomy / methods. Humans. NAD / analysis. Necrosis. Prospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):592-8 [11180892.001]
  • [Cites] Radiology. 2005 Jul;236(1):132-9 [15987969.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):912-20 [10679662.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jan;178(1):47-51 [11756085.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):390-6 [14735342.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Apr;5(2):337-52 [9019355.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2894-900 [10576369.001]
  • [Cites] Radiology. 2004 Apr;231(1):143-9 [14990816.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):657-62; discussion 662-4 [10843361.001]
  • [Cites] Ann Surg. 1989 Aug;210(2):127-38 [2667471.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1354-60 [16332494.001]
  • [Cites] Endoscopy. 2000 Aug;32(8):591-7 [10935786.001]
  • [Cites] AJR Am J Roentgenol. 2006 Oct;187(4):W333-40 [16985103.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2452-63 [10861420.001]
  • [Cites] J Urol. 2002 Dec;168(6):2401-5 [12441926.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):275-83 [12679313.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):274-6 [8472130.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):52-8 [12513961.001]
  • [Cites] Br J Surg. 2003 Jan;90(1):122 [12520590.001]
  • (PMID = 17393259.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0U46U6E8UK / NAD
  •  go-up   go-down


8. Laca L, Urdzik J, Dobrota FM, Polácek H: [Limitations of liver resections]. Rozhl Chir; 2009 Mar;88(3):127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limitations of liver resections].
  • Evaluation of the functional reserve before resectional performance and sufficient rest of liver parenchyma function is essential for the surgeon.
  • From these factors, the decision based on operability, the maximum extent of liver parenchyma resection and the severity of post-operative course.
  • In the period from December 2003 to December 2008, at the Dept of Transplant and Vascular surgery, JLF UK Martin, have been performed 161 resections of the liver in 144 patients, of which 91 large resections performances in the liver (hemihepatektomies or greater performance).
  • Of 91 major resection performance in the liver was 62 (68%) performed by anatomical boundaries of individual segments, in remaining 29 (32%) resections was reflected more to the localization of tumor itself as anatomical subdivision called combined anatomical and non-antomical resection.
  • Radical resection R0 has been achieved in 76% of malignant tumors.
  • In the post-operative course in 17% experienced complications, most often to the hematoma and biloma in place of the resection area, pleural effusion and 8 patients had postoperative liver dysfunction.
  • Of this group, 5 patients had made volumetric examinations, and in all was the volume of residual liver parenchyma < 30% of the total volume of functional liver.
  • The survival of patients was affected mainly by extent of resection, histological type of tumor, radicality of resection and necessity of the complex surgical procedures.
  • Based on our evaluation of the results of a group of patients was arranged scheme measures for planning resectional procedures of the liver in our department.
  • These include the adjustment of laboratory parameters, management of jaundice, preference of anatomical resections and volumetric examinations in patients with an estimated loss of more than 60-70% functional parenchyma of liver.
  • [MeSH-minor] Female. Humans. Liver / physiopathology. Male. Middle Aged. Postoperative Complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526944.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


9. Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V: Biomarkers of liver fibrosis. Adv Clin Chem; 2008;46:131-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers of liver fibrosis.
  • Liver biopsy, due to its limitations and risks, is an imperfect gold standard for assessing the severity of the most frequent chronic liver diseases.
  • This chapter summarized the advantages and the limits of the available biomarkers of liver fibrosis.
  • The mean diagnostic value for the diagnosis of advanced fibrosis assessed using standardized area under the receiver operating characteristics (ROC) curves was 0.84 [95% confidence interval (CI), 0.83-0.86], without significant difference between the causes of liver disease, hepatitis C, hepatitis B, alcoholic or nonalcoholic fatty liver disease.
  • Due to the evidence-based data, health authorities in some countries have already approved validated biomarkers as first-line procedure for the staging of liver fibrosis.
  • This overview of evidence-based data suggests that biomarkers could be used as an alternative to liver biopsy for the assessment of fibrosis stage in the four more common chronic liver diseases: C virus (HCV), hepatitis B virus (HBV), hepatitis nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD).
  • [MeSH-major] Liver Cirrhosis / diagnosis
  • [MeSH-minor] Biomarkers. Biopsy. Humans. Liver / pathology. Patents as Topic

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004189.001).
  • [ISSN] 0065-2423
  • [Journal-full-title] Advances in clinical chemistry
  • [ISO-abbreviation] Adv Clin Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 109
  •  go-up   go-down


11. Sadamori H, Yagi T, Iwagaki H, Matsuda H, Shinoura S, Umeda Y, Ohara N, Yanai H, Ogino T, Tanaka N: Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol; 2009 Apr;24(4):574-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation.
  • AIM: We evaluated the expression of hepatitis C virus (HCV) antigen on liver grafts by immunohistochemical staining (IHS) using IG222 monoclonal antibody (mAb) against HCV-envelope 2 (E2).
  • METHODS: The study material was 84 liver biopsy specimens obtained from 28 patients who underwent living donor liver transplantation (LDLT) for HCV infection.
  • There was no significant correlation between the IHS grades using IG222 mAb and serum HCV-RNA levels when data of 84 liver biopsy specimens were analyzed.
  • CONCLUSIONS: Constant HCV-E2 expression was observed in liver biopsy specimens obtained 1 month or longer.
  • The strong HCV-E2 expression on liver grafts were associated with recurrent hepatitis C after LDLT, but the serum HCV-RNA levels were not.
  • [MeSH-major] Hepacivirus / isolation & purification. Hepatitis C / virology. Immunohistochemistry. Liver / virology. Liver Cirrhosis / surgery. Liver Transplantation. Living Donors. Viral Envelope Proteins / analysis


12. Kaliciński P, Ismail H, Broniszczak D, Teisserye J, Bacewicz L, Markiewicz-Kijewska M, Szymczak M, Nachulewicz P, Dembowska-Bagińska B, Kluge P, Kościesza A, Kowalski A, Stefanowicz M, Kasprzyk W, Krawczyk M: Non-resectable hepatic tumors in children - role of liver transplantation. Ann Transplant; 2008;13(2):37-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-resectable hepatic tumors in children - role of liver transplantation.
  • BACKGROUND: There is a group of children with primary hepatic tumors which can not be resected by conventional partial liver resection.
  • Total hepatectomy followed by liver transplantation may be the only solution in such cases.
  • Authors reviewed own experience with the liver transplantation for unresectable tumors in children and assessed the possible indications and role of transplantation in these patients.
  • MATERIAL AND METHODS: Liver transplantation was performed in 17 children with unresectable hepatic tumors out of total number of 350 children transplanted.
  • Hepatocarcinoma was present in 8 children, hepatoblastoma in 6 and benign giant hemangioma in 3.
  • There was no other option for the treatment which would lead to the oncological cure of children with malignant tumors.
  • RESULTS: Survival within whole group is 75.5% (13 of 17 pts), 3 children died of malignant tumor recurrence, one of other causes.
  • All 3 children with benign tumors are alive and well.
  • CONCLUSIONS: Liver transplantation should be considered as option in the treatment of all children with unresectable hepatic tumors.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hemangioma / surgery. Hepatectomy. Hepatoblastoma / surgery. Liver Neoplasms / surgery. Liver Transplantation


13. Wang WL, Zheng SS, Xu X, Liang TB, Jin J, Shen Y, Zhang M, Wu J: [Clinical evaluation of emergency liver transplantation for patients with benign end-stage liver diseases]. Zhonghua Yi Xue Za Zhi; 2005 Dec 28;85(49):3460-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of emergency liver transplantation for patients with benign end-stage liver diseases].
  • OBJECTIVE: To evaluate the efficacy of emergency liver transplantation in treating patients with benign end-stage liver diseases and explore the possible prognostic factors.
  • CONCLUSION: Emergency liver transplantation is an effective treatment to salvage patients in end-stage.
  • [MeSH-major] Hepatitis B / surgery. Liver Cirrhosis / surgery. Liver Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686060.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


14. Deaciuc IV, Song Z, Peng X, Barve SS, Song M, He Q, Knudsen TB, Singh AV, McClain CJ: Genome-wide transcriptome expression in the liver of a mouse model of high carbohydrate diet-induced liver steatosis and its significance for the disease. Hepatol Int; 2008 Mar;2(1):39-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide transcriptome expression in the liver of a mouse model of high carbohydrate diet-induced liver steatosis and its significance for the disease.
  • PURPOSE: To perform a large-scale gene profiling of the liver in a mouse model of fatty liver induced by high carbohydrate (sucrose) diet (HCD) to gain a deeper insight into potential mechanisms of diet-induced hepatic steatosis.
  • HCD feeding led to marked liver steatosis without inflammation or necrosis.
  • The genes that underwent expression changes perform a large variety of molecular functions, and the vast majority of these have never been tested before in non-alcoholic fatty liver of nutritional origin.
  • They reveal novel aspects of the disease and allow identification of candidate genes that may underlie the initiation of hepatic steatosis and progression to non-alcoholic steatohepatitis.
  • CONCLUSIONS: HCD-fed laboratory animals provide a model of early non-alcoholic fatty liver disease resembling the disease in humans.
  • The genome wide gene profiling of the liver reveals the complexity of the disease, unravels novel aspects of HCD-induced hepatic steatosis, and helps elucidate its nature and mechanisms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr Biochem. 2007 Mar;18(3):184-95 [17296492.001]
  • [Cites] Am J Clin Nutr. 1980 May;33(5):1108-39 [6989228.001]
  • [Cites] Ann Intern Med. 2005 Nov 15;143(10):722-8 [16287793.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1663-74 [16285964.001]
  • [Cites] Hepatology. 2005 Oct;42(4):905-14 [16175602.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):20010-20 [15753094.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):99-105 [15860251.001]
  • [Cites] CMAJ. 2005 Mar 29;172(7):899-905 [15795412.001]
  • [Cites] Clin Biochem. 2005 Mar;38(3):203-17 [15708540.001]
  • [Cites] Alcohol. 2004 Aug;34(1):67-79 [15670668.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1387-95 [15565570.001]
  • [Cites] Biochimie. 2004 Nov;86(11):839-48 [15589694.001]
  • [Cites] Proc Natl Acad Sci U S A. 1964 Nov;52:1255-63 [14231450.001]
  • [Cites] J Biol Chem. 1962 Dec;237:3640-8 [13990010.001]
  • [Cites] Hepatology. 1999 May;29(5):1602-4 [10216149.001]
  • [Cites] Adv Enzyme Regul. 1996;36:199-226 [8869748.001]
  • [Cites] Ann N Y Acad Sci. 1982;393:32-47 [6959560.001]
  • [Cites] Clin Liver Dis. 2004 Aug;8(3):559-74, ix [15331064.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36650-9 [15194686.001]
  • [Cites] J Clin Invest. 2004 Jul;114(2):147-52 [15254578.001]
  • [Cites] Alcohol. 2004 Feb;32(2):113-27 [15163562.001]
  • [Cites] Am J Clin Nutr. 2004 Mar;79(3):502-9 [14985228.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):219-27 [14739091.001]
  • [Cites] J Hepatol. 2003 Dec;39(6):978-83 [14642615.001]
  • [Cites] J Lipid Res. 2003 Apr;44(4):846-53 [12562844.001]
  • [Cites] Am J Clin Nutr. 2003 Jan;77(1):43-50 [12499321.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;967:19-27 [12079831.001]
  • [Cites] Hepatology. 2001 May;33(5):1239-58 [11343254.001]
  • [Cites] J Soc Biol. 2001;195(3):243-8 [11833461.001]
  • [Cites] Semin Liver Dis. 2001;21(1):89-104 [11296700.001]
  • [Cites] Gene Expr. 2000;9(1-2):63-75 [11097425.001]
  • [Cites] Eur J Biochem. 2001 Jan;268(1):1-6 [11121095.001]
  • [Cites] J Clin Invest. 1996 May 1;97(9):2081-91 [8621798.001]
  • [Cites] Environ Res. 1992 Oct;59(1):238-49 [1425514.001]
  • [Cites] J Pediatr. 2005 Dec;147(6):835-8 [16356442.001]
  • (PMID = 19669278.001).
  • [ISSN] 1936-0533
  • [Journal-full-title] Hepatology international
  • [ISO-abbreviation] Hepatol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2716868
  •  go-up   go-down


15. Rakela B J: [Liver disease recurrence after liver transplantation]. Rev Med Chil; 2010 Apr;138(4):504-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver disease recurrence after liver transplantation].
  • [Transliterated title] Recurrencia de la enfermedad hepática primaria después del trasplante hepático.
  • Liver transplantation has become a standard option in the management of patients with end-stage liver disease.
  • It is now evident that the most common etiology of long-term graft dysfunction is the recurrence of the primary liver disease.
  • Autoimmune liver disorders such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis recur between 15 to 30% of the graft recipients.
  • The clinical expression of this recurrence tends to be milder; the diagnosis is only established in many patients by findings in the liver biopsy.
  • The recurrence of hepatitis C virus infection is characterized by an accelerated progression towards cirrhosis and hepatic failure due to the lack of an effective immunoprophylaxis program and an effective antiviral therapy.
  • The liver from these patients, apart from producing this abnormal protein, is otherwise normal, and has been used as an organ for recipients in dire need of a liver transplant, such as patients with hepatocellular carcinoma.
  • This approach is known as domino liver transplantation.
  • As these recipients are followed long term, they may develop de novo amyloidosis.
  • In summary, the underlying liver condition that led to endstage liver disease and liver transplantation may recur after liver transplantation.
  • The clinical expression of the recurrence of the hepatic disease is modulated by the immunosuppression program unless we have an effective immunoprophylaxis and antiviral agents such as in hepatitis B.
  • [MeSH-major] Cholangitis, Sclerosing. Hepatitis, Autoimmune. Liver Cirrhosis, Biliary / prevention & control. Liver Transplantation. Postoperative Complications


16. Gunes D, Uysal KM, Cecen E, Cakmakci H, Ozer E, Akgur FM, Olgun N: Stromal-predominant mesenchymal hamartoma of the liver with elevated serum alpha-fetoprotein level. Pediatr Hematol Oncol; 2008 Sep;25(7):685-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal-predominant mesenchymal hamartoma of the liver with elevated serum alpha-fetoprotein level.
  • Mesenchymal hamartoma of the liver (MHL) is an uncommon, benign, tumor-like lesion and is usually diagnosed in the first 2 years of life.
  • He was successfully treated with total excision of the pedunculated large tumor without any complication.
  • [MeSH-major] Hamartoma / diagnosis. Liver Diseases / diagnosis. alpha-Fetoproteins / analysis
  • [MeSH-minor] Diagnosis, Differential. Humans. Infant. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Male. Mesoderm / pathology

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18850482.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


17. Gouw AS, Zeng W, Buiskool M, Platteel I, van den Heuvel MC, Poppema S, de Jong KP, Molema G: Molecular characterization of the vascular features of focal nodular hyperplasia and hepatocellular adenoma: a role for angiopoietin-1. Hepatology; 2010 Aug;52(2):540-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) are two hepatic nodular lesions of different etiologies.
  • FNH, a polyclonal lesion, is assumed to be a regenerative reaction following a vascular injury, whereas HCA is a monoclonal, benign neoplastic lesion.
  • This was based on reports of morphologically abnormal hepatic vasculature and nodular lesions in transgenic models of hepatocytic overexpression of angiopoietin-1 (Ang-1), a member of the angiopoietin family, which is crucially involved in vascular morphogenesis and homeostasis.
  • We investigated gene and protein expression of members of the angiopoietin system and vascular endothelial growth factor A (VEGF-A) and its receptors in 9 FNH samples, 13 HCA samples, and 9 histologically normal livers.
  • [MeSH-major] Adenoma, Liver Cell / blood supply. Angiopoietin-1 / physiology. Focal Nodular Hyperplasia / pathology. Liver Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683953.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-1
  •  go-up   go-down


18. Malik R, Saich R, Rahman T, Hodgson H: During thioacetamide-induced acute liver failure, the proliferative response of hepatocytes to thyroid hormone is maintained, indicating a potential therapeutic approach to toxin-induced liver disease. Dig Dis Sci; 2006 Dec;51(12):2235-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] During thioacetamide-induced acute liver failure, the proliferative response of hepatocytes to thyroid hormone is maintained, indicating a potential therapeutic approach to toxin-induced liver disease.
  • In toxic liver injury, proliferation of preexisting hepatocytes helps restore liver mass and function.
  • While loss of liver mass per se stimulates hepatocyte proliferation, exogenous mitogens have a potential role in enhancing liver regeneration.
  • The aim of this study was to characterize the effects of the mitogen, tri-iodothyonine, on the regenerative capacity of hepatocytes during thioacetamide-induced liver failure.
  • Liver cell proliferation was assessed and comparison made with other control groups receiving tri-iodothyonine or vehicle only.
  • We conclude that the ability of hepatocytes in the midzonal areas of rat liver to proliferate in response to tri-iodothyonine is maintained during severe acute toxic injury.
  • [MeSH-major] Cell Proliferation / drug effects. Hepatocytes / drug effects. Liver Failure, Acute / pathology. Triiodothyronine / pharmacology
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Liver Regeneration / drug effects. Male. Mitogens / pharmacology. Random Allocation. Rats. Thioacetamide

  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1990 May;10(3):332-6 [2195108.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):535-52 [1716045.001]
  • [Cites] Am J Surg. 2002 Apr;183(4):457-63 [11975936.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 1994 Aug;85(2):157-62 [7994560.001]
  • [Cites] Liver. 1999 Dec;19(6):519-25 [10661686.001]
  • [Cites] Semin Liver Dis. 2003 Aug;23(3):203-15 [14523674.001]
  • [Cites] Physiol Rev. 1986 Jul;66(3):499-541 [2426724.001]
  • [Cites] J Surg Res. 2001 Aug;99(2):385-96 [11469916.001]
  • [Cites] Hepatology. 1994 Nov;20(5):1237-41 [7927257.001]
  • [Cites] Am J Pathol. 1991 Nov;139(5):1099-109 [1683163.001]
  • [Cites] Oncogene. 1997 Feb 20;14(7):857-63 [9047393.001]
  • [Cites] Semin Cell Dev Biol. 2002 Dec;13(6):425-31 [12468243.001]
  • [Cites] Hepatology. 2003 Jan;37(1):79-86 [12500192.001]
  • [Cites] Dig Dis Sci. 2002 Oct;47(10):2170-8 [12395888.001]
  • [Cites] Science. 1997 Apr 4;276(5309):60-6 [9082986.001]
  • [Cites] Life Sci. 2003 Jan 3;72 (7):851-61 [12479984.001]
  • [Cites] Hepatology. 1998 Apr;27(4):1013-20 [9537441.001]
  • [Cites] FASEB J. 1996 Aug;10(10):1118-28 [8751714.001]
  • [Cites] Am J Pathol. 1996 Mar;148(3):815-24 [8774136.001]
  • [Cites] J Hepatol. 2003 May;38(5):583-90 [12713868.001]
  • [Cites] Arch Surg. 2001 Dec;136(12):1377-80 [11735863.001]
  • [Cites] Lab Invest. 1983 Feb;48(2):224-30 [6823098.001]
  • [Cites] Endocrinology. 2002 Mar;143(3):979-84 [11861522.001]
  • [Cites] Int J Exp Pathol. 2000 Apr;81(2):145-57 [10762442.001]
  • (PMID = 17080250.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitogens; 06LU7C9H1V / Triiodothyronine; 075T165X8M / Thioacetamide
  •  go-up   go-down


19. Sańko-Resmer J, Paczek L, Wyzgał J, Ziółkowski J, Ciszek M, Alsharabi A, Grzelak I, Paluszkiewicz R, Patkowski W, Krawczyk M: Biliary liver cirrhosis secondary to cystic fibrosis: a rare indication for liver transplantation. Transplant Proc; 2006 Jan-Feb;38(1):212-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary liver cirrhosis secondary to cystic fibrosis: a rare indication for liver transplantation.
  • As more effective therapies prolong the lives of patients with cystic fibrosis, there are now more patients in this population diagnosed with liver diseases.
  • Liver transplantation is an accepted method of treatment for children with cystic fibrosis and portal hypertension.
  • We present our first case of orthotopic liver transplantation performed in a 29-year-old man with cystic fibrosis.
  • [MeSH-major] Cystic Fibrosis / diagnosis. Liver Cirrhosis, Biliary / etiology. Liver Cirrhosis, Biliary / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Humans. Liver Function Tests. Male. Treatment Outcome


20. Khunamornpong S, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Na Chiangmai W, Young RH: Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia. Am J Surg Pathol; 2007 Dec;31(12):1788-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia.
  • The potential for adenocarcinoma metastatic to the ovary to mimic primary mucinous neoplasms is a well-known issue to surgical pathologists, most of the recent literature emphasizing pancreatic and various other origins for the ovarian metastases.
  • Although an origin in the gallbladder or extrahepatic bile ducts is acknowledged for some cases little information exists on tumors originating within the intrahepatic bile ducts.
  • Thirteen presented with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The hepatic tumors were radiologically detected before the ovarian lesion in 2 cases.
  • Hepatic and ovarian masses were simultaneously detected by preoperative radiologic studies or at exploratory laparotomy in 10 cases.
  • In the remaining 4 cases, the hepatic lesions were detected postoperatively.
  • Microscopically, surface implants were observed in 80% of tumors, multinodular growth in 48%, and infiltrative stromal invasion (including microinvasionlike foci as it would be applied if the tumors were primary) in 86%.
  • The tumors most closely mimicked primary mucinous neoplasms although a resemblance to other mullerian neoplasms was also seen.
  • Foci often mimicked mucinous borderline tumors of typical type or with intraepithelial carcinoma and benign-appearing mucinous epithelium was seen in 62% of tumors.
  • Intrahepatic cholangiocarcinoma should be included in the list of origins of possible ovarian metastatic tumors that mimic primary ovarian mucinous neoplasia, particularly in parts of the world where cholangiocarcinoma of the liver is relatively common.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Cholangiocarcinoma / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Bile Ducts, Intrahepatic / pathology. Diagnosis, Differential. Female. Humans. Middle Aged


21. Natsume T, Okazumi S, Takayama W, Takeda A, Iwasaki K, Makino H, Sasagawa S, Cho A, Kouno T, Kondo S, Sunouchi K, Asano T, Ochiai T: Evaluation of the hepatic blood flow increase in the cases with liver metastasis and prediction of patent cases of liver metastasis using dynamic CT. Hepatogastroenterology; 2007 Sep;54(78):1745-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the hepatic blood flow increase in the cases with liver metastasis and prediction of patent cases of liver metastasis using dynamic CT.
  • BACKGROUND/AIMS: This study aimed to measure hepatic blood flow increase in cases with liver metastasis and to diagnose minimal metastasis which cannot be visualized by imaging modalities.
  • METHODOLOGY: The evaluation of hepatic arterial flow increase was performed quantitatively by newly devised index ELR (early-late-ratio) using dynamic computed tomographic (CT) scanning with contrast media.
  • RESULTS: The ratio of the cases with liver metastasis was significantly higher than that of normal liver control.
  • It was revealed that the ratio was correlated with microvessel proliferation in the liver around the metastasis by examination of surgical specimen.
  • CONCLUSIONS: ELR not only was useful to evaluate hepatic blood flow increase in the cases with liver metastasis but also could be applied to predict the patent group with micrometastasis.
  • [MeSH-major] Liver / blood supply. Liver Neoplasms / blood supply. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Regional Blood Flow. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Blood Flow Velocity. Case-Control Studies. Cell Proliferation. Densitometry. Hepatic Artery / pathology. Humans. Microcirculation. Neoplasm Metastasis. Time Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019709.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


22. Morana G, Cugini C, Mucelli RP: Small liver lesions in oncologic patients: characterization with CT, MRI and contrast-enhanced US. Cancer Imaging; 2008;8 Spec No A:S132-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small liver lesions in oncologic patients: characterization with CT, MRI and contrast-enhanced US.
  • Focal liver lesions (FLLs) are frequently discovered during ultrasound examinations either in healthy subjects without a clinical history of cancer or during staging or follow-up procedures in oncologic patients or in routine surveillance of hepatopathic patients.
  • In oncologic patients, the liver is the most common target of metastatic disease and accurate detection and characterisation of FLLs is prognostically fundamental during the initial staging as well as before and after pre-operative chemotherapy, as it can help to identify patients who are most likely to benefit from liver surgery.
  • Moreover, early detection of primary or secondary liver malignancies increases the possibility of curative surgical resection or successful percutaneous ablation.
  • As many FLLs in these patients are benign, a precise and preferably non-invasive method of differentiation from malignant metastatic nodules is needed.
  • [MeSH-major] Liver / pathology. Magnetic Resonance Imaging / methods. Neoplasms / pathology. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2007 Jan;242(1):162-74 [17090710.001]
  • [Cites] Eur Radiol. 2006 Jul;16(7):1599-609 [16552507.001]
  • [Cites] Ulster Med J. 2007 Jan;76(1):22-5 [17288301.001]
  • [Cites] Cancer Imaging. 2007;7:2-9 [17293303.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):529-36 [16802201.001]
  • [Cites] Eur Radiol. 2007 Apr;17(4):1066-73 [17072617.001]
  • [Cites] Med Sci Monit. 2007 May;13 Suppl 1:111-5 [17507895.001]
  • [Cites] Diagn Interv Radiol. 2007 Jun;13(2):81-6 [17562512.001]
  • [Cites] BMC Cancer. 2007;7:171 [17767722.001]
  • [Cites] World J Gastroenterol. 2007 Dec 7;13(45):5963-70 [18023084.001]
  • [Cites] Eur Radiol. 2008 Mar;18(3):477-85 [17960390.001]
  • [Cites] Eur Radiol. 2008 May;18(5):903-10 [18193234.001]
  • [Cites] Invest Radiol. 2008 Jul;43(7):504-11 [18580333.001]
  • [Cites] Eur J Radiol. 2008 Sep;67(3):440-7 [18430538.001]
  • [Cites] Abdom Imaging. 2009 Mar-Apr;34(2):193-209 [18317833.001]
  • [Cites] AJR Am J Roentgenol. 2000 Oct;175(4):1111-20 [11000175.001]
  • [Cites] Radiology. 2002 Jan;222(1):95-102 [11756711.001]
  • [Cites] Acad Radiol. 2002 Aug;9 Suppl 2:S476-9 [12188313.001]
  • [Cites] Top Magn Reson Imaging. 2002 Jun;13(3):117-50 [12357078.001]
  • [Cites] Radiology. 2002 Dec;225(3):766-72 [12461259.001]
  • [Cites] Neurology. 2003 Oct 14;61(7):1015-6 [14557588.001]
  • [Cites] Radiol Med. 2004 Jul-Aug;108(1-2):71-81 [15269691.001]
  • [Cites] J Ultrasound Med. 2004 Dec;23(12):1557-68 [15557299.001]
  • [Cites] J Clin Ultrasound. 2005 May;33(4):164-72 [15856516.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Aug;4(3):406-9 [16109526.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jan;186(1):158-67 [16357396.001]
  • [Cites] Magn Reson Med Sci. 2005 Dec 31;4(4):175-86 [16543702.001]
  • [Cites] AJR Am J Roentgenol. 2006 Apr;186(4):1059-66 [16554579.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1699-705 [16586537.001]
  • [Cites] Radiol Med. 2006 Apr;111(3):392-419 [16683086.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2007 Jan;19(1):3-14 [17206071.001]
  • (PMID = 18852087.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC2582502
  •  go-up   go-down


23. d'Assignies G, Couvelard A, Bahrami S, Vullierme MP, Hammel P, Hentic O, Sauvanet A, Bedossa P, Ruszniewski P, Vilgrain V: Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology; 2009 Feb;250(2):407-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors.
  • PURPOSE: To prospectively correlate multidetector computed tomographic (CT) perfusion measurement of pancreatic endocrine tumors with tumor microvascular density (MVD) assessed by using histologic techniques and to determine whether perfusion CT parameters differ between tumor grades.
  • Thirty-six patients (15 men, 21 women; mean age, 53 years; range, 18-78 years) with resectable pancreatic endocrine tumors underwent presurgical dynamic perfusion CT.
  • Multidetector CT perfusion data were analyzed to calculate tumor and normal pancreatic blood flow, blood volume, mean transit time, and permeability-surface area product.
  • Multidetector CT perfusion parameters were compared with intratumoral MVD by using the Spearman correlation coefficient and with World Health Organization (WHO) classification, tumor size, tumor proliferation index, hormonal profile, and presence of metastases by using Mann-Whitney tests.
  • RESULTS: High correlation (r = 0.620, P < .001) was observed between tumor blood flow and intratumoral MVD.
  • Blood flow was significantly higher (P = .02) in the group of benign tumors (WHO 1) than in the groups of tumors of indeterminate prognosis (WHO 2) or well-differentiated carcinomas (WHO 3).
  • Blood flow was significantly higher in tumors with a proliferation index of 2% or less (P = .005) and in those without histologic signs of microscopic vascular involvement (P = .008).
  • Mean transit time was longer in tumors with lymph node (P = .02) or liver (P = .05) metastasis.
  • CONCLUSION: Perfusion CT is feasible in patients with pancreatic endocrine tumors and reflects MVD.
  • [MeSH-major] Neovascularization, Pathologic / radiography. Pancreatic Neoplasms / blood supply. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Radiographic Image Interpretation, Computer-Assisted. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095784.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Terán A, Casafont F, Fábrega E, Martínez-Taboada VM, Rodríguez-Valverde V, Pons-Romero F: [Adult-onset Still's disease with liver failure requiring liver transplantation]. Gastroenterol Hepatol; 2009 Dec;32(10):681-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-onset Still's disease with liver failure requiring liver transplantation].
  • [Transliterated title] Enfermedad de Still del adulto con desarrollo de insuficiencia hepática que precisa trasplante hepático.
  • We present the case of a 23-year-old man with fever of unknown origin, who developed acute liver failure 2 months after symptom onset, requiring an urgent liver transplantation.
  • The diagnosis of adult-onset Still's disease was established after the reappearance of symptoms after transplantation, and high doses of corticosteroids were used to control disease activity.
  • [MeSH-major] Liver Failure / etiology. Liver Transplantation. Still's Disease, Adult-Onset / surgery


25. Heilmaier C, Sutter R, Lutz AM, Seifert B, Willmann JK: [Dynamic MRI of the liver with parallel acquisition technique: characterization of focal liver lesions and analysis of the hepatic vasculature in a single MRI session]. Rofo; 2008 May;180(5):440-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dynamic MRI of the liver with parallel acquisition technique: characterization of focal liver lesions and analysis of the hepatic vasculature in a single MRI session].
  • [Transliterated title] Dynamische MRT der leber mit paralleler akquisitionstechnik: charakterisierung fokaler leberläsionen und analyse des gefässstatus in einem untersuchungsgang.
  • PURPOSE: To retrospectively evaluate the performance of breath-hold contrast-enhanced 3D dynamic parallel gradient echo MRI (pMRT) for the characterization of focal liver lesions (standard of reference: histology) and for the analysis of hepatic vasculature (standard of reference: contrast-enhanced 64-detector row computed tomography;.
  • MATERIALS AND METHOD: Two blinded readers independently analyzed preoperative pMRT data sets (1.5T-MRT) of 45 patients (23 men, 22 women; 28 - 77 years, average age, 48 years) with a total of 68 focal liver lesions with regard to image quality of hepatic arteries, portal and hepatic veins, presence of variant anatomy of the hepatic vasculature, as well as presence of portal vein thrombosis and hemodynamically significant arterial stenosis.
  • In addition, both readers were asked to identify and characterize focal liver lesions.
  • RESULTS: Based on histology, the 68 liver lesions were found to be 42 hepatocellular carcinomas (HCC), 20 metastases, 3 cholangiocellular carcinomas (CCC) as well as 1 dysplastic nodule, 1 focal nodular hyperplasia (FNH) and 1 atypical hemangioma.
  • Overall, the diagnostic accuracy was high for both readers (91 - 100 %) in the characterization of these focal liver lesions with an excellent interobserver agreement (kappa-values of 0.89 [metastases], 0.97 [HCC] and 1 [CCC]).
  • Anatomical variants of the hepatic arteries, hepatic veins and portal vein as well as thrombosis of the portal vein were reliably detected by pMRT.
  • It allows reliable detection and characterization of focal liver lesions as well as the depiction of hepatic vascular variants, portal vein thrombosis, and arterial stenosis.
  • Introducing pMRT in routine liver MRI may be another step towards a simplified diagnostic work-up prior to liver surgery.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Liver / blood supply. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Arterial Occlusive Diseases / diagnosis. Bile Duct Neoplasms / blood supply. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Female. Focal Nodular Hyperplasia / diagnosis. Hemangioma / diagnosis. Hepatic Artery / pathology. Hepatic Veins / pathology. Humans. Male. Middle Aged. Observer Variation. Portal Vein / pathology. Retrospective Studies. Sensitivity and Specificity. Thrombosis / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18438745.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Polacco M, Vitale A, Valmasoni M, D'Amico F, Gringeri E, Brolese A, Zanus G, Neri D, Carraro A, Pauletto A, Romanelli E, Lo Bello S, Cillo U: Liver resection associated with mini porto-caval shunt as salvage treatment in patients with progression of hepatocellular carcinoma before liver transplantation: a case report. Transplant Proc; 2010 May;42(4):1378-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection associated with mini porto-caval shunt as salvage treatment in patients with progression of hepatocellular carcinoma before liver transplantation: a case report.
  • Tumor progression before orthotopic liver transplantation (OLT) is the main cause of dropouts from waiting lists among patients with hepatocellular carcinoma (HCC).
  • Performing a porto-caval shunt (PCS) before parenchymal liver transection has the potential to allow an extended hepatectomy in patients with decompensated liver cirrhosis, reducing portal hyperflow and therefore the sinusoidal shear-stress on the remnant liver.
  • We report the case of a 59-year-old man affected by hepatitis C virus (HCV)-related decompensated liver cirrhosis (Child Pugh score presentation, C-10; Model for End Stage Liver Disease score, 18) and HCC (2 lesions of 2 and 2.8 cm).
  • The patient began the evaluation to join the OLT waiting list, but, in the 3 months required to complete the evaluation, he developed tumor progression: 3 HCC lesions, the largest 1 with a diameter of about 4.4 cm.
  • After appropriate preoperative studies, the patient underwent a major liver resection (trisegmentectomy) after side-to-side PCS by interposition of an iliac vein graft from a cadaveric donor.
  • Associating a partial side-to-side PCS with hepatic resection may represent a potential salvage therapy for patients with decompensated cirrhosis and HCC progression beyond listing criteria for OLT.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Cirrhosis / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods. Portasystemic Shunt, Transjugular Intrahepatic / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20534307.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


27. Zurbuchen U, Holmer C, Lehmann KS, Stein T, Roggan A, Seifarth C, Buhr HJ, Ritz JP: Determination of the temperature-dependent electric conductivity of liver tissue ex vivo and in vivo: Importance for therapy planning for the radiofrequency ablation of liver tumours. Int J Hyperthermia; 2010 Feb;26(1):26-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of the temperature-dependent electric conductivity of liver tissue ex vivo and in vivo: Importance for therapy planning for the radiofrequency ablation of liver tumours.
  • INTRODUCTION: Knowledge about the changes in the electric conductivity during the coagulation process of radiofrequency ablation of the liver is a prerequisite for the predictability of produceable thermonecrosis in the liver.
  • MATERIALS AND METHODS: Continuous measurements of the electric conductivity sigma in ex vivo porcine liver (n = 25) were done during the coagulation and cooling process at the temperature range of the radiofrequency ablation at a frequency of 470 kHz relevant for the radiofrequency ablation.
  • Measurements of the electric conductivity were performed in both perfused porcine liver (n = 3) and a human surgical specimen from a colorectal liver metastasis.
  • At 37 degrees C, the specific conductance sigma in the healthy perfused porcine liver was 0.52 S/m, 0.55 S/m and 0.57 S/m (mean 0.55 S/m).
  • The electric conductivity of the human colorectal liver metastasis was clearly higher.
  • [MeSH-major] Catheter Ablation / methods. Electric Conductivity. Liver / physiopathology. Liver Neoplasms / physiopathology
  • [MeSH-minor] Animals. Colorectal Neoplasms / pathology. Humans. Swine. Temperature

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20100050.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Culafić DM, Lekić NS, Kerkez MD, Mijac DD: Liver actinomycosis mimicking liver tumour. Vojnosanit Pregl; 2009 Nov;66(11):924-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver actinomycosis mimicking liver tumour.
  • BACKGROUND: The liver actinomycosis is a rare disease associated with complex differentiation from the liver metastases or hepatocellular carcinoma.
  • Diagnostic procedures that followed, including abdominal ultrasound and computed tomography led us to the diagnosis of metastatic liver disease of unknown etiology with pleural and pericardial effusion.
  • Intraoperatively, the presence of liver pseudotumor without malignancy in the liver was confirmed.
  • Histological examination confirmed the diagnosis of liver actinomycosis.
  • CONCLUSION: Liver actinomycosis has a nonspecific presentation, often mimicking liver tumor.
  • A timely diagnosis as well as a combined surgical and antibiotic therapy is necessary in the treatment of patients with primary disease and prevention of complications.
  • [MeSH-major] Actinomycosis / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Errors. Female. Humans. Middle Aged


29. Yuan Y, Song B, Wu B, Xu J, Li YC: [Research on relationship between preoperative CT volumetry of donor' s liver and intraoperative weight measurement of liver for living related liver transplantation]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun;38(3):526-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Research on relationship between preoperative CT volumetry of donor' s liver and intraoperative weight measurement of liver for living related liver transplantation].
  • OBJECTIVE: To investigate the relationship between the donor liver volume calculated by 16-slice multi-detector-row CT before living related liver transplantation (LRLT) and the hepatic weight measured during the operation, and try to get an equation to express the relation of associating volume with weight of transplanted liver.
  • The imaging data at the hepatic venous phase was used for whole and partial liver volumetry processed or measured on a dedicated image post-processing workstation.
  • The resected part of donor liver was weighed during the operation.
  • Statistical analysis was used to test the relationship between the CT-measured liver volume and the actual weight of resected liver part, and the relationship was expressed by scatter graph and linear equation.
  • RESULTS: The mean of liver volumes calculated by CT before operation was (699. 47 +/- 140.
  • 18) mL, the mean weight of donated livers measured during operation was (532. 14+/- 98.
  • CONCLUSION: The correlation equation between the donor liver volume calculated by CT preoperatively and the grafted liver weight measured during operation can be used to accurately estimate the desired liver mass for LRLT, which is very helpful for donor selection and preoperative planning.
  • [MeSH-major] Liver / anatomy & histology. Liver / radiography. Liver Transplantation. Living Donors. Preoperative Period. Tomography, X-Ray Computed


30. Reddy MS, Smith L, Jaques BC, Agarwal K, Hudson M, Talbot D, Manas DM: Do laparoscopy and intraoperative ultrasound have a role in the assessment of patients with end-stage liver disease and hepatocellular carcinoma for liver transplantation? Transplant Proc; 2007 Jun;39(5):1474-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do laparoscopy and intraoperative ultrasound have a role in the assessment of patients with end-stage liver disease and hepatocellular carcinoma for liver transplantation?
  • BACKGROUND: Liver transplantation is the treatment of choice for patients with end-stage liver disease (ESLD) and early hepatocellular carcinoma (HCC), Routine laparoscopy with intraoperative ultrasound was employed in an attempt to improve patient selection for transplantation.
  • METHODS: We retrospectively reviewed the clinical notes and transplant database of all patients with ESLD complicated by HCC, being assessed for liver transplantation, from January 2000 to April 2005.
  • RESULTS: Twenty-five patients with ESLD and HCC underwent assessment for liver transplantation.
  • One patient was found to have lesser curvature lymphadenopathy, Two patients had major vascular involvement noted in the explanted liver.
  • CONCLUSIONS: As an additional investigation, laparoscopy did not improve staging or alter the management of patients with HCC being assessed for liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Failure / surgery. Liver Neoplasms / surgery. Ultrasonography
  • [MeSH-minor] Humans. Laparoscopy. Monitoring, Intraoperative. Neoplasm Staging. Retrospective Studies


31. van Gulik TM, Kloek JJ, Ruys AT, Busch OR, van Tienhoven G, Lameris JS, Rauws EA, Gouma DJ: [Improved treatment results in hilar cholangiocarcinoma after transition to more extensive procedure: 20 years experience AMC]. Ned Tijdschr Geneeskd; 2010;154:A1815
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the result of surgical treatment of patients with hilar cholangiocarcinoma (HCCA) before and after the transition from predominantly local bile duct resections to more extensive resections including partial liver resection in order to achieve complete tumour resection in the Academic Medical Center, Amsterdam (The Netherlands).
  • A more extended multidisciplinary surgical approach combining bile duct resection with partial liver resection was applied as of 1998.
  • RESULTS: In 18 patients (15.3%) a benign lesion was found in the resection specimen.
  • Among the other 99 patients with microscopically confirmed HCCA, 21 (72%) of 29 patients had undergone bile duct resection in combination with partial liver resection in period 2 as compared to 17 (24%) of 70 patients in period 1.
  • The margin tumour free resection rate increased from 20% in period 1 to 59% in period 2.
  • CONCLUSION: More extensive resection of HCCA in combination with partial liver resection in the setting of a multidisciplinary approach led to a higher rate of margin free resections and improved 5-year survival.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Biliary Tract Surgical Procedures. Female. Follow-Up Studies. Humans. Klatskin Tumor / mortality. Klatskin Tumor / surgery. Male. Middle Aged. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858305.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. Jang HJ, Kim TK, Wilson SR: Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. Eur J Radiol; 2009 Dec;72(3):418-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound.
  • OBJECTIVE: To determine the diagnostic efficacy of arterial phase contrast-enhanced ultrasound (CEUS) for characterizing small hepatic nodules (1-2 cm) in patients with high-risk for hepatocellular carcinoma (HCC).
  • MATERIALS AND METHODS: Over 12 months, CEUS was performed in 59 patients at high-risk for HCC with small hepatic nodules (1-2 cm; mean, 1.5 cm).
  • The diagnosis of HCC was made regardless of the presence or absence of washout.
  • Verification of diagnosis was made by liver transplantation (n=13), biopsy (n=12), resection (n=3) or clinical and imaging follow-up for at least 12 months (n=31).
  • RESULTS: At of the time of CEUS, the 59 nodules were diagnosed as HCC in 26 and benign lesions in 33, including 20 regenerative/dysplastic nodules (RN/DN), 11 hemangiomas, and 2 focal fat sparing.
  • CONCLUSIONS: Arterial phase vascular intensity and pattern of CEUS are highly accurate for the diagnosis of small (1-2 cm) HCC and hemangioma in liver cirrhosis.
  • On CEUS, arterial phase hypervascularity without a hemangioma-pattern alone may be sufficient for diagnosis of small HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / ultrasonography. Fluorocarbons. Image Enhancement / methods. Liver Cirrhosis / ultrasonography. Liver Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834687.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Definity; 0 / Fluorocarbons
  •  go-up   go-down


33. Qian Y, Fan JG: Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int; 2005 May;4(2):173-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity, fatty liver and liver cancer.
  • BACKGROUND: It has been suggested that obesity and fatty liver may be associated with the morbidity and mortality of liver cancer, and the early diagnosis and effective treatment of fatty liver coupled with liver cancer are supposed to improve the prognosis of obese patients.
  • This review was attempted to understand the relationship between obesity, fatty liver and liver cancer.
  • DATA RESOURCES: An English-language literature search using PUBMED (1990-2004) on obesity, fatty liver and liver cancer and other related articles in Chinese.
  • RESULTS: Obesity is associated with the risk of death from all cancers and from cancers at individual sites including liver cancer, and it is an independent risk factor for hepatocellular carcinoma (HCC) in patients with alcoholic cirrhosis and cryptogenic cirrhosis.
  • More frequent surveillance for HCC may be warranted in obese patients with fatty liver and attempts should be made to interrupt the progression from simple hepatic steatosis to steatohepatitis, cirrhosis and ultimately HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Fatty Liver / epidemiology. Liver Neoplasms / epidemiology. Obesity / epidemiology

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908310.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 27
  •  go-up   go-down


34. Rodríguez G, Gallego S, Breidenassel C, Moreno LA, Gottrand F: Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents? Nutr Hosp; 2010 Sep-Oct;25(5):712-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents?
  • Pediatric obesity has increased dramatically all over the world and nonalcoholic fatty liver disease (NAFLD) is one of the most frequent complications associated with excess adiposity.
  • NAFLD causes serum transaminase elevation and liver disease, which could end up in fibrosis, cirrhosis and eventually hepatocellular carcinoma.
  • The aim of the present article is to review the role of serum liver enzyme assessment as a suitable non invasive predictor of NAFLD in children.
  • Although serum liver enzyme elevation does not accurately measure liver damage, it may be a valuable and non invasive test to screen NAFLD in children and adolescents and a marker to control NAFLD evolution.
  • [MeSH-major] Fatty Liver / diagnosis. Liver / enzymology. Liver Function Tests. Obesity / complications. Transaminases / analysis


35. Oliveri F, Coco B, Ciccorossi P, Colombatto P, Romagnoli V, Cherubini B, Bonino F, Brunetto MR: Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol; 2008 Oct 28;14(40):6154-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases.
  • AIM: To investigate the usefulness of transient elastography by Fibroscan (FS), a rapid non-invasive technique to evaluate liver fibrosis, in the management of chronic hepatitis B virus (HBV) carriers.
  • METHODS: In 297 consecutive HBV carriers, we studied the correlation between liver stiffness (LS), stage of liver disease and other factors potentially influencing FS measurements.
  • We identified the cut-offs of 7.5 and 11.8 kPa for the diagnosis of fibrosis >or= S3 and cirrhosis respectively, showing 93.9% and 86.5% sensitivity, 88.5% and 96.3% specificity, 76.7% and 86.7% positive predictive value (PPV), 97.3% and 96.3% negative predictive value (NPV) and 90.1% and 94.2% diagnostic accuracy.
  • CONCLUSION: FS is a non-invasive tool to monitor liver disease in chronic HBV carriers, provided that the pattern of biochemical activity is taken into account.
  • In the inactive carrier, it identifies non-HBV-related causes of liver damage and transient reactivations.
  • In CHB patients, it may warrant a more appropriate timing of control liver biopsies.
  • [MeSH-major] Alanine Transaminase / blood. Carrier State. Clinical Enzyme Tests. Elasticity Imaging Techniques. Hepatitis B / diagnosis. Hepatitis B, Chronic / diagnosis. Liver / pathology. Liver Cirrhosis / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2003;39 Suppl 1:S3-25 [14708673.001]
  • [Cites] Ultrasound Med Biol. 2003 Dec;29(12):1705-13 [14698338.001]
  • [Cites] J Viral Hepat. 1996 Nov;3(6):277-83 [8947878.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Hepatology. 2005 Jan;41(1):48-54 [15690481.001]
  • [Cites] Hepatology. 2005 Oct;42(4):838-45 [16121354.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):175-9 [16394849.001]
  • [Cites] Gut. 2006 Mar;55(3):403-8 [16020491.001]
  • [Cites] Semin Liver Dis. 2006 May;26(2):130-41 [16673291.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1511-7 [17133503.001]
  • [Cites] Hepatology. 2007 Feb;45(2):507-39 [17256718.001]
  • [Cites] J Viral Hepat. 2007 May;14(5):360-9 [17439526.001]
  • [Cites] Gut. 2007 Jul;56(7):968-73 [17255218.001]
  • [Cites] Hepatology. 2007 Oct;46(4):1057-70 [17654702.001]
  • [Cites] Hepatology. 2008 Feb;47(2):380-4 [18095306.001]
  • [Cites] Hepatology. 2008 Feb;47(2):592-5 [18098325.001]
  • [Cites] J Hepatol. 2008 Apr;48(4):606-13 [18222014.001]
  • [Cites] J Hepatol. 2008 May;48(5):835-47 [18334275.001]
  • [Cites] J Hepatol. 2002 Feb;36(2):263-70 [11830339.001]
  • [Cites] IEEE Trans Ultrason Ferroelectr Freq Control. 2002 Apr;49(4):436-46 [11989699.001]
  • [Cites] Gut. 2003 Mar;52(3):416-9 [12584226.001]
  • [Cites] Gut. 2003 Mar;52(3):420-4 [12584227.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Mar;18(3):246-52 [12603523.001]
  • [Cites] Am J Gastroenterol. 2003 Oct;98(10):2261-7 [14572577.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • (PMID = 18985805.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC2761576
  •  go-up   go-down


36. Esheba GE, Pate LL, Longacre TA: Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol; 2008 Apr;32(4):600-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
  • Clear cell carcinoma (CCC) of the ovary is the surface epithelial neoplasm most often confused with primitive germ cell tumors, particularly yolk sac tumor (YST) and dysgerminoma.
  • Recent studies suggest that glypican-3 (GPC3), an oncofetal protein expressed in fetal liver and malignant tumors of hepatocytic lineage, is also expressed in germ cell tumors, particularly YST.
  • To investigate whether GPC3 is useful in distinguishing YST from ovarian CCC, we studied the expression of GPC3 in a large series of ovarian neoplasms and compared it to the expression profiles of CK7 and alpha-fetoprotein.
  • Tissue microarrays containing over 400 benign and malignant ovarian neoplasms, including 34 CCCs were stained with monoclonal GPC3 (clone 1G12, Biomosaics, Burlington, VT).
  • These arrays contained a wide assortment of ovarian surface epithelial neoplasms and sex cord stromal neoplasms, as well as germ cell tumors.
  • All but one YST (97%), including those associated with mixed germ cell tumor were positive for GPC3, whereas all teratomas and embryonal carcinomas were negative.
  • The syncytiotrophoblastic cells in the germ cell tumors and placental villi included in the arrays were also positive for GPC3.
  • Most CCCs (83%) were completely negative for GPC3, as were 99% serous, 94% endometrioid, and 100% mucinous tumors.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Endodermal Sinus Tumor / chemistry. Glypicans / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7 / analysis. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277882.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / alpha-Fetoproteins; 0 / oncofetal antigens
  •  go-up   go-down


37. Brady MJ, Thomas J, Wong TZ, Franklin KM, Ho LM, Paulson EK: Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology; 2009 Feb;250(2):523-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nodules were defined histologically or by size change (malignant, n = 37) or stability for more than 1 year (benign, n = 58).
  • Diameter, mean attenuation, SUV(max), and SUV ratio (nodule SUV(max)/liver SUV(avg)) were compared with t test and receiver operating characteristic analyses.
  • Applying a further cutoff of SUV ratio > 2.5 enabled identification of 22 of 37 metastatic lesions and exclusion of all fluorodeoxyglucose-avid benign nodules.
  • [MeSH-major] Adrenal Gland Neoplasms / radionuclide imaging. Adrenal Gland Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods


38. Takamura K, Miyake H, Fujii M, Nishi M, Tashiro S, Shimada M: Multiple hepatic angiomyolipomas with a solitary omental angiomyolipoma. J Med Invest; 2005 Aug;52(3-4):218-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple hepatic angiomyolipomas with a solitary omental angiomyolipoma.
  • Angiomyolipoma (AML) is a rare benign tumor that occurs most commonly in the kidney.
  • Lesions in the liver are usually solitary and multiple AMLs of the liver are extremelyrare.
  • Furthermore, extra renal or hepatic AML are rarely found.
  • We report an unusual case of a 34-year-old man with a solitary omental AML and multiple hepatic AMLs.
  • At the age of 23, the patient underwent right nephrectomy and enucleation of a left renal tumor because of bilateral AMLs.
  • At the age of 34, more than 6 lesions in the liver and an enlarged solitary omental AML were discovered.
  • The omental tumor, 50 x 40mm, 49g, was extirpated; it was well-defined and encapsulated a soft elastic mass.
  • Histologically it was an epithelioid AML and positive for the melanogenesis-related marker HMB-45, the same as the earlier right renal tumor.
  • We describe the first case of a solitary omental AML, which had metastasized, and with more than 6 hepatic AMLs.
  • [MeSH-major] Angiomyolipoma / pathology. Liver Neoplasms / pathology. Omentum. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167542.001).
  • [ISSN] 1343-1420
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Strunk H, Börner N, Stuckmann G, Hadizadeh D: [Pitfalls in contrast-enhanced liver sonography: consequences for the practice]. Radiologe; 2005 Jun;45(6):529-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pitfalls in contrast-enhanced liver sonography: consequences for the practice].
  • [Transliterated title] Pitfalls in der kontrastverstärkten Lebersonographie: Konsequenzen für die Praxis.
  • Contrast-enhanced sonography performed as phase inversion harmonic imaging is a promising new technique for detection and characterization of hepatic foci.
  • It has been reported that malignant liver tumors can be differentiated from benign entities with almost 100% sensitivity and that diagnosis of the type is possible with an accuracy of over 90%.
  • In summary, most hepatic lesions can be correctly characterized by supplemental use of enhanced sonography; practitioners should nevertheless be aware of atypical phenomena to be able to critically evaluate the findings.
  • [MeSH-major] Contrast Media. Diagnostic Errors / prevention & control. Image Enhancement / methods. Liver Neoplasms / diagnostic imaging. Liver Neoplasms / secondary. Microbubbles. Ultrasonography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Interpretation, Computer-Assisted / methods. Liver / diagnostic imaging. Male. Middle Aged. Practice Guidelines as Topic. Practice Patterns, Physicians'. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiol Med. 2004 Mar;107(3):174-86; quiz 187-8 [15031683.001]
  • [Cites] Radiology. 2004 Aug;232(2):420-30 [15286314.001]
  • [Cites] Radiologe. 2001 Jan;41(1):8-15 [11220102.001]
  • [Cites] Rofo. 2003 Jun;175(6):835-43 [12811698.001]
  • [Cites] Int J Colorectal Dis. 2003 Jan;18(1):63-72 [12458384.001]
  • [Cites] Rofo. 2000 Jan;172(1):61-7 [10719465.001]
  • [Cites] Acad Radiol. 2003 Jul;10 (7):739-50 [12862283.001]
  • [Cites] Radiographics. 2004 Jul-Aug;24(4):921-35 [15256618.001]
  • [Cites] Rofo. 2003 Jul;175(7):889-91 [12847642.001]
  • [Cites] Eur Radiol. 1999;9 Suppl 3:S382-7 [10602934.001]
  • [Cites] Radiology. 2004 Sep;232(3):799-809 [15284434.001]
  • [Cites] Eur Radiol. 2001;11 Suppl 3:E15-26 [11793049.001]
  • [Cites] Radiology. 2000 Apr;215(1):153-61 [10751481.001]
  • [Cites] Int J Colorectal Dis. 2001 Aug;16(4):247-56 [11515685.001]
  • [Cites] Radiol Med. 2004 Mar;107(3):155-65 [15031681.001]
  • [Cites] Radiology. 2003 Dec;229(3):798-805 [14563903.001]
  • [Cites] Rofo. 2000 Apr;172(4):361-6 [10961221.001]
  • [Cites] Z Gastroenterol. 2001 Apr;39(4):287-9, 292-4 [11367977.001]
  • [Cites] Radiology. 2000 Aug;216(2):411-7 [10924562.001]
  • [Cites] Rofo. 2004 Nov;176(11):1607-16 [15497079.001]
  • (PMID = 15912320.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


40. Guo KJ, Song SW, Zhao MF, Ge CL, Xu YH, Ma G, Meng FB, Guo RX, Tian YL: [Indications, technique and efficacy of organ preserving pancreatectomy]. Zhonghua Wai Ke Za Zhi; 2010 Sep 15;48(18):1375-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To discuss the proper surgical management of pancreatic benign and low-grade malignant potential neoplasm.
  • There were 9 cases underwent duodenum-preserving resection of the head of the pancreas, 29 cases underwent spleen-preserving distal pancreatectomy, 11 cases underwent middle segmental pancreatectomy, 23 cases underwent tumor extirpation of huge pancreatic cancer in pancreatic head and body.
  • Pancreatic fistula was found in 5 cases among who accepted tumor extirpation of huge pancreatic cancer in pancreatic head and body, and liver metastasis was found in 3 cases at 6, 12, 16 months after surgery respectively.
  • CONCLUSIONS: Organ preserving pancreatectomy can obviously reduce operative injury to patients, its therapeutic effect is similar to that of classical operation, it is the first option of benign and low-grade malignant potential neoplasm.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pancreatic Neoplasms / surgery. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092570.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


41. Yamaguchi K, Konomi H, Kobayashi K, Ogura Y, Sonoda Y, Kawamoto M, Nakano K, Tanaka M: Total pancreatectomy for intraductal papillary-mucinous tumor of the pancreas: reappraisal of total pancreatectomy. Hepatogastroenterology; 2005 Sep-Oct;52(65):1585-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total pancreatectomy for intraductal papillary-mucinous tumor of the pancreas: reappraisal of total pancreatectomy.
  • Intraductal papillary-mucinous tumor (IPMT) of the pancreas is characterized by extensive intraductal spread and favorable outcome even in its invasive stage.
  • RESULTS: Total pancreatectomy was performed due to massive involvement of the entire pancreas in two patients, positive surgical margins on frozen section in one, benign IPMT with concomitant pancreatic cancers in one and recurrent IPMT in the remnant pancreas after distal pancreatectomy for IPMT in the other.
  • Two patients had severe infection including liver abscess in one and pneumonia in the other.
  • Long-term follow-up of the four patients revealed that three patients had hypoglycemic attacks, two diabetic retinopathy and two fatty liver.
  • CONCLUSIONS: Total pancreatectomy would be indicated as a treatment of benign or malignant IPMT with extensive involvement when patients' condition permits and gives a chance of cure, although careful long-term medical care and follow-up are essential.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Dilatation, Pathologic. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201122.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


42. Zhong G, Hu J, Chen Z, Luo Y, Zhang Y, Yin Y, Li W, Yi Z, Chen G: [Effect of the formulae for calming the liver and suppressing YANG on lymphocyte proteome in migraine rats with syndrome of hyperactivity of liver-YANG]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Jan;35(1):70-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of the formulae for calming the liver and suppressing YANG on lymphocyte proteome in migraine rats with syndrome of hyperactivity of liver-YANG].
  • OBJECTIVE: To explore the molecular mechanism of the formulae for calming the liver and suppressing YANG in migraine rat model with syndrome of hyperactivity of the liver-YANG.
  • METHODS: A rat model of migraine with hyperactivity of liver-YANG was established through electrical trigeminal ganglion stimulation and syndrome of oral administration of Fuzi decoction.
  • The total proteins of the lymphocyte in the rats were separated by immobilized pH gradient-based 2-dimensional gel electrophoresis (2-DE), and the 2-DE image was analyzed by PDQuest 7.0 software.
  • RESULTS: The formulae for calming the liver and suppressing YANG could also improve headache.
  • Well-resolution and reproducible 2-DE patterns of rat lymphocyte from normal, model, and therapy tissues were obtained.
  • CONCLUSION: Differences occur in the expression of lymphocyte proteins in migraine rats with syndrome of hyperactivity of liver-YANG after treatment with the formulae for calming the liver and suppressing YANG, and the 11 identified protein spots may be associated with its mechanism.
  • [MeSH-minor] Animals. Diagnosis, Differential. Drugs, Chinese Herbal / therapeutic use. Electric Stimulation. Liver / physiopathology. Male. Proteins / analysis. Proteins / metabolism. Rats. Rats, Sprague-Dawley. Yin-Yang

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Migraine.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20130367.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Proteins; 0 / Proteome
  •  go-up   go-down


43. Bara T, Bancu S, Bara T Jr, Mureşan M, Bancu L, Azamfirei L, Podeanu D, Mureşan S: [Gastric stromal tumor with liver and subcutaneus metastasis. Case report]. Chirurgia (Bucur); 2009 Sep-Oct;104(5):621-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric stromal tumor with liver and subcutaneus metastasis. Case report].
  • [Transliterated title] Tumoră stromală gastrică cu metastaze hepatice şi subcutanate. Prezentare de caz.
  • The gastrointestinal stromal tumours expand from the undefine mezenchimal cells of the intestinal wall and the origin is in the Cajal interstitial cells.
  • Very importants factors for grading are the tumour localisation, the invasion of serosa or mucosa, the dimensions of tumour and the number of mytosis.
  • We present a case with haemoragic gastric stromal tumour, with small dimensions, which was initially diagnosed as a "benign" tumour.
  • Seven years after the operation, the patient presented voluminous liver metastases.
  • CONCLUSIONS: The gastrointestinals stromal tumours represent a very rare group of digestive tract tumors, with malignant potentially evolution; the first choice of treatment is surgery, with complete ablation of the tumour.
  • The medical treatment with Glivec is necessary in case of reccurence or metastases; the stromal tumours present a strange evolution, for this reason all the patients must be under medical observation, for the rest of their life.
  • [MeSH-major] Gastrointestinal Stromal Tumors / secondary. Liver Neoplasms / secondary. Soft Tissue Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19943565.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


44. Sahani DV, Kalva SP, Fischman AJ, Kadavigere R, Blake M, Hahn PF, Saini S: Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol; 2005 Jul;185(1):239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.
  • OBJECTIVE: The objective of our study was to assess the relative performance of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET for the detection of liver metastases from adenocarcinoma of the colon and pancreas.
  • MATERIALS AND METHODS: Imaging data of 34 patients (23 men, 11 women; age range, 44-78 years) with adenocarcinoma of the colon (n = 27) or adenocarcinoma of the pancreas (n = 7) who had undergone mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET were retrospectively reviewed for the presence and number of liver metastases.
  • RESULTS: Thirty patients had hepatic metastases and four had no hepatic metastases according to the standard of reference.
  • MRI detected more hepatic metastases than FDG PET (p = 0.016).
  • CONCLUSION: In patients with colon and pancreatic adenocarcinoma, high-spatial-resolution mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET were comparable in the detection of patients with liver metastases.
  • However, significantly more and smaller liver metastases were detected on MRI than on FDG PET.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / pathology. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972430.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42Z2K6ZL8P / Manganese; 5V5IOJ8338 / Pyridoxal Phosphate; 9G34HU7RV0 / Edetic Acid; P28BIW0UTB / N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
  •  go-up   go-down


45. Malartic C, Morel O, Akerman G, Tulpin L, Desfeux P, Barranger E: [Role of mifepristone for the treatment of uterine fibroid]. Gynecol Obstet Fertil; 2008 Jun;36(6):668-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mifepristone, a progesterone receptor antagonist steroid, can reduce uterine fibroid tumours' growth by several pathways.
  • A significant decrease in fibroid tumours and uterine volume concomitant with better quality of life scores can be obtained with a daily administration of Mifepristone 5mg.
  • Observed adverse outcomes are hot flushes (38%), elevated hepatic enzymes (4%) and benign endometrial hyperplasia (28%).
  • Data suggest that many invasive procedures could be avoided with the routine use of Mifepristone for fibroid tumours care.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Leiomyoma / drug therapy. Mifepristone / therapeutic use. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Dose-Response Relationship, Drug. Endometrial Hyperplasia / chemically induced. Female. Hot Flashes / chemically induced. Humans. Liver / enzymology. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18539512.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 320T6RNW1F / Mifepristone
  • [Number-of-references] 42
  •  go-up   go-down


46. Diederich S, Padge B, Vossas U, Hake R, Eidt S: Application of a single needle type for all image-guided biopsies: results of 100 consecutive core biopsies in various organs using a novel tri-axial, end-cut needle. Cancer Imaging; 2006;6:43-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Biopsies were obtained of liver (n = 32), lymph nodes (n = 17), thyroid (n = 11), lung (n = 9), adrenal (n = 9), pelvis (n = 6), chest wall/pleura (n = 6), mediastinum (n = 4), lytic bone lesions (n = 2), retroperitoneum (n = 1), muscle (n = 1), pancreas (n = 1), peritoneum (n = 1).
  • In 77 cases a malignant (40 metastases, 37 primary tumours) and in 23 a benign lesion was diagnosed.
  • Of the 23 benign lesions a specific diagnosis was possible in 22.
  • CONCLUSION: Percutaneous image-guided biopsy using the described full-core end-cut needle resulted in a specific diagnosis in 99/100 consecutive biopsies in various organs with a low complication rate.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Equipment Design. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasms / diagnosis. Neoplasms / pathology. Radiography, Interventional. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright International Cancer Imaging Society.
  • [Cites] BJU Int. 2002 Jan;89(1):40-3 [11849158.001]
  • [Cites] Eur Radiol. 2004 Mar;14(3):375-82 [14551726.001]
  • [Cites] Eur Urol. 2004 Mar;45(3):287-91 [15036672.001]
  • [Cites] Chest. 2004 Sep;126(3):748-54 [15364752.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jan;164(1):221-4 [7998543.001]
  • [Cites] Radiology. 1998 Aug;208(2):303-18 [9680552.001]
  • [Cites] Radiology. 2005 Feb;234(2):631-7 [15673500.001]
  • [Cites] Eur Urol. 2005 Mar;47(3):297-301 [15716189.001]
  • [Cites] AJR Am J Roentgenol. 1993 Dec;161(6):1293-7 [8249745.001]
  • (PMID = 16766268.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1693774
  •  go-up   go-down


47. Burton JR Jr, Rosen HR: Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States. Clin Gastroenterol Hepatol; 2005 Jul;3(7):700-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States.
  • BACKGROUND & AIMS: Hepatitis C virus (HCV)-related liver failure is the leading indication for liver transplantation (LT).
  • To gain insight into how transplant centers are dealing with this issue and whether published prognostic factors are being used, we conducted a survey of liver transplant centers across the US in late 2003.
  • However, less than half thought international normalized ratio (INR), Model for End-Stage Liver Disease (MELD), and bilirubin were important factors.
  • [MeSH-major] Hepatitis C / surgery. Liver Transplantation / statistics & numerical data

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206504.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Yamaguchi K, Nakamura M, Shirahane K, Konomi H, Torata N, Hamasaki N, Kawakita M, Tanaka M: Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas. Dig Liver Dis; 2005 Mar;37(3):190-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.
  • BACKGROUND: Serum carcinoembryonic antigen (highly specific) and carbohydrate antigen 19-9 (highly sensitive) have been used as tumour markers for pancreatobiliary cancers.
  • A novel urine tumour marker, diacetylspermine, was compared with the two conventional serum tumour markers in 125 patients with pancreatobiliary diseases.
  • RESULTS: When the diagnosis of benign or malignant condition was examined, the sensitivity of urine diacetylspermine (75%) was higher than that of serum carcinoembryonic antigen (44%; P=0.048) and the same as that of serum carbohydrate antigen 19-9 (75%).
  • [MeSH-major] Biliary Tract Neoplasms / urine. Biomarkers, Tumor / urine. Pancreatic Neoplasms / diagnosis. Spermine / analogs & derivatives. Spermine / urine

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888284.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  •  go-up   go-down


49. Yin Z, Wang X, Li N, Ni X, Jiang F, Li Y, Li J: Immunological advantage on small bowel graft induced by simultaneously transplanted liver in porcine auxiliary liver/small bowel transplantation. Transplant Proc; 2006 Dec;38(10):3251-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological advantage on small bowel graft induced by simultaneously transplanted liver in porcine auxiliary liver/small bowel transplantation.
  • BACKGROUND: We developed a new porcine model for auxiliary liver/small bowel transplantation (LSBT).
  • The possible immunological advantage on small bowel graft induced by simultaneously transplanted liver in the large animal was assessed.
  • CONCLUSIONS: An immunological advantage on intestinal graft can be induced by simultaneously transplanted liver in auxiliary LSBT.
  • The liver graft may reduce the risk of intestinal rejection and thus protect the bowel graft.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Intestine, Small / transplantation. Liver Transplantation / physiology. Transplantation, Homologous / physiology

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175239.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


50. Târcoveanu E, Vlad N, Moldovanu R, Georgescu St, Bradea C, Lupaşu C, Crumpei F, Vasilescu A, Strat V: [Pyogenic liver abscesses]. Chirurgia (Bucur); 2008 Jul-Aug;103(4):417-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pyogenic liver abscesses].
  • BACKGROUND: Pyogenic liver abscesses were a relative rare disease.
  • In the last decades the management of the liver abscesses was changed due to the new imaging and surgical techniques.
  • AIM: To evaluate the clinical features, imaging techniques and treatment of the liver abscesses.
  • RESULTS: Of the 71 patients with liver abscesses, 39 (54.9%) were included in group I and 32 (45.1%) in group II.
  • The male/female ratio was 49/22; liver abscesses were more frequent to the males, in group I (63.3%) and more frequent to the women, in group II (63.6%) (p = 0.035).
  • We noted, as associated disease: diabetes--16% (N = 12), liver cirrhosis--7% (N = 5), malignancies--4.2% (N = 3).
  • The etiology was diverse: 25.4% after hepatic hydatid cysts, 12.7% with biliary origin, 22.5% with hematogenous and phlebitis origin and 39.4% with unknown origin (cryptogenetic).
  • Treatment of the liver abscesses was surgical, by open (87.3%) or laparoscopic approach (8.5%), and percutaneous (ultrasound guided punction)--2.8%.
  • The intraoperative mean dimension of the liver abscesses was 74.26 +/- 4.35 mm (range 30-160), similar with dimensions measured by echography 72.29 +/- 4.84 mm (range 12-179)--p < 10(-3).
  • Univariate analysis revealed as prognosis factors for intraoperative bleeding, diameter of the liver abscess (p < 10(-3)), dimension of the residual cavity (p < 10(-3)) and the pus volume (p < 10(-3)).
  • CONCLUSIONS: Pyogenic liver abscess is a challenging disease with high rate of postoperative morbidity.
  • Most of the abscesses are unique and situated in the right lobe of the liver.
  • The imaging techniques, especially ultrasound exam and CT-scan, are essential for the diagnosis and the treatment of liver abscesses.
  • [MeSH-major] Hepatectomy. Liver Abscess, Pyogenic / microbiology. Liver Abscess, Pyogenic / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780615.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


51. Cione GP, Cerbone D, Di Benedetto A, Podio P, Cimmino G, Parmeggiani D, Peltrini A, Lombardi V, Perrotta M: [Intrahepatic biliary cystadenoma: case report]. Suppl Tumori; 2005 May-Jun;4(3):S48-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the OMS classification of the epithelial benign neoplasm of the liver, the adenomas represent the most important group.
  • The biliar cistoadenoma (BCA) represents a not frequent neoplasm of the liver that has origin on the inside of the liver, and less frequently from the extrahepatic biliar system.
  • The real difficulty is represented by differential diagnosis from the other cystic lesions of the liver and by the need of its radical excision and therefore of real hepatectomy.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Cystadenoma

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437897.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


52. Marangoni G, Faraj W, Sethi H, Rela M, Muiesan P, Heaton N: Liver resection in liver transplant recipients. Hepatobiliary Pancreat Dis Int; 2008 Dec;7(6):590-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection in liver transplant recipients.
  • BACKGROUND: Liver resection after liver transplantation is a relatively uncommon procedure.
  • Indications for liver resection include hepatic artery thrombosis (HAT), non-anastomotic biliary stricture (ischemic biliary lesions), liver abscess, liver trauma and recurrence of hepatocellular carcinoma (HCC).
  • METHODS: Eleven resections at a mean of 59 months after liver transplantation were made over 18 years.
  • Indications for liver resection included HCC recurrence in 4 patients, ischemic cholangiopathy, segmental HAT, sepsis and infected hematoma in 2 each, and ischemic segment IV after split liver transplantation in 1.
  • There were 3 deaths, two from HCC recurrence and one from post-transplant lymphoproliferative disorder.
  • CONCLUSIONS: Liver resection in liver transplant recipients is safe, and has good outcome in selected patients and avoids re-transplantation in the majority of patients.
  • [MeSH-major] Hepatectomy / statistics & numerical data. Liver Transplantation / statistics & numerical data. Postoperative Complications / mortality. Postoperative Complications / surgery
  • [MeSH-minor] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Child. Child, Preschool. Cholestasis / mortality. Cholestasis / surgery. Follow-Up Studies. Hospital Mortality. Humans. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Reoperation / mortality. Reoperation / statistics & numerical data. Thrombosis / mortality. Thrombosis / surgery


53. Uggowitzer MM, Gotschuli G, Reiter H, Petek B: [Contrast-enhanced sonography of the liver]. Radiologe; 2005 Jan;45(1):24-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contrast-enhanced sonography of the liver].
  • [Transliterated title] Kontrastverstärkte Sonographie der Leber.
  • The detection rate of liver lesions using ultrasonography is 53-77%, rendering this method inferior to CT and MRI.
  • Characterization of focal liver lesions with ultrasound contrast agents follows known features of iodine- and gadolinium-containing contrast agents, but compared to CT and MRI sensitive visualization of intratumoral vessels takes place in real time.
  • In addition to very high diagnostic accuracy in differentiating benign from malignant lesions, detectability of tumors of nonhepatocellular origin is increased significantly and direct assessment of treatment success with minimally invasive tumor ablative interventions in the liver is possible.
  • The active principle of ultrasound contrast agents, examination technique as well as distinguishing features and appearance of various, frequently observed focal liver lesions are illustrated by cases from our department.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnostic imaging. Contrast Media / administration & dosage. Image Enhancement. Liver Diseases / diagnostic imaging. Liver Neoplasms / diagnostic imaging. Liver Neoplasms / secondary
  • [MeSH-minor] Cysts / diagnostic imaging. Diagnosis, Differential. Focal Nodular Hyperplasia / diagnostic imaging. Half-Life. Hemangioma / diagnostic imaging. Hepatic Veins / diagnostic imaging. Humans. Liver / blood supply. Liver / diagnostic imaging. Microbubbles. Neovascularization, Pathologic / diagnostic imaging. Phospholipids / pharmacokinetics. Polysaccharides / pharmacokinetics. Sensitivity and Specificity. Sulfur Hexafluoride / pharmacokinetics. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2002 Mar;12 (3):537-44 [11870467.001]
  • [Cites] Rofo. 2003 Jun;175(6):835-43 [12811698.001]
  • [Cites] J Ultrasound Med. 2001 Feb;20(2):89-98 [11211141.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jan;180(1):143-9 [12490493.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):475-83 [12594549.001]
  • [Cites] Radiology. 2000 Nov;217(2):558-63 [11058660.001]
  • [Cites] Invest Radiol. 2000 Apr;35(4):253-9 [10764094.001]
  • [Cites] AJR Am J Roentgenol. 2001 Oct;177(4):799-805 [11566675.001]
  • [Cites] Radiographics. 2004 Jul-Aug;24(4):921-35 [15256618.001]
  • [Cites] J Ultrasound Med. 2001 May;20(5):517-23 [11345109.001]
  • [Cites] AJR Am J Roentgenol. 2002 Nov;179(5):1273-9 [12388513.001]
  • [Cites] Eur J Surg. 1993 May;159(5):275-81 [8103361.001]
  • [Cites] Radiology. 2004 Sep;232(3):799-809 [15284434.001]
  • [Cites] Radiology. 2002 Jan;222(1):95-102 [11756711.001]
  • [Cites] Eur J Radiol. 2004 Jun;51 Suppl:S19-23 [15311434.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):509-14 [2154912.001]
  • [Cites] Liver Transpl. 2004 Feb;10 (2 Suppl 1):S34-8 [14762837.001]
  • [Cites] AJR Am J Roentgenol. 1991 Oct;157(4):731-9 [1892027.001]
  • [Cites] Ultrasound Med Biol. 1999 Nov;25(9):1341-52 [10626621.001]
  • [Cites] Br J Radiol. 1998 Oct;71(850):1026-32 [10211062.001]
  • [Cites] Invest Radiol. 2001 Jan;36(1):50-5 [11176261.001]
  • [Cites] Radiology. 2000 Apr;215(1):153-61 [10751481.001]
  • [Cites] Invest Radiol. 2004 Apr;39(4):216-22 [15021325.001]
  • [Cites] Radiology. 1999 Jun;211(3):643-9 [10352586.001]
  • [Cites] Ultrasound Med Biol. 2002 Mar;28(3):287-95 [11978408.001]
  • [Cites] J Clin Ultrasound. 2002 Oct;30(8):465-71 [12242734.001]
  • [Cites] Radiology. 2000 Aug;216(2):411-7 [10924562.001]
  • [Cites] Radiology. 2003 May;227(2):361-70 [12649417.001]
  • [Cites] Radiology. 2001 Sep;220(3):661-7 [11526264.001]
  • (PMID = 15565382.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / Polysaccharides; 0 / contrast agent BR1; 127279-08-7 / SHU 508; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


54. Vennarecci G, Ettorre GM, Lorusso R, Santoro R, Visco G, Santoro E: [Surgical prospects for liver metastases]. Chir Ital; 2007 Jan-Feb;59(1):27-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical prospects for liver metastases].
  • The recent advances in liver surgery have made it possible to perform liver resections in an increasing number of patients with consequent improvement in the results.
  • This coincides with an amplification of the indications to liver surgery for metastases.
  • Besides the development of radiological procedures as applied to liver surgery and more effective chemotherapy protocols, the actual approach to patients with liver metastases is shared by three figures - the surgeon, the radiologist and the oncologist.
  • Currently it has been shown that liver resections for metastases are possible with a meaningful increase of survival in the case of colorectal and neuroendocrine liver metastases and in selected cases of non-colorectal non-neuroendocrine metastases.
  • From the technical point of view the most remarkable aspect is the possibility of expanding the criteria of resectability by means of liver resections in one or two steps associated with portal vein embolisation or ligation of a portal branch.
  • It is also possible to perform iterative liver resections and liver transplantation in selected cases of neuroendocrine liver metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neuroendocrine Tumors / secondary. Neuroendocrine Tumors / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361929.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 67
  •  go-up   go-down


55. Tanikawa K, Torimura T: Studies on oxidative stress in liver diseases: important future trends in liver research. Med Mol Morphol; 2006 Mar;39(1):22-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies on oxidative stress in liver diseases: important future trends in liver research.
  • Oxidative stress has recently been shown to play an important role in various liver diseases.
  • Therefore, further studies on oxidative stress in liver diseases are urgently required.
  • [MeSH-major] Biomedical Research / trends. Liver / pathology. Liver Diseases / metabolism. Liver Diseases / pathology. Oxidative Stress

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1117-23 [10833486.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1796-807 [14724832.001]
  • [Cites] Kurume Med J. 1964;11:177-81 [14301621.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):568-71 [11832470.001]
  • [Cites] Circulation. 2003 Jul 29;108(4):414-9 [12860911.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):307-12 [11201732.001]
  • [Cites] J Clin Pathol. 1997 May;50(5):401-6 [9215123.001]
  • [Cites] J Hepatol. 2005 Oct;43(4):599-605 [16024129.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2198-205 [10445550.001]
  • [Cites] Hepatol Res. 2005 Oct;33(2):97-9 [16216545.001]
  • [Cites] J Hepatol. 1999 Sep;31(3):430-4 [10488700.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1399-410 [11984526.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):291-300 [12105857.001]
  • [Cites] J Hepatol. 2000 Oct;33(4):616-22 [11059866.001]
  • [Cites] J Clin Invest. 2000 Jul;106(2):171-6 [10903330.001]
  • [Cites] Gastroenterol Jpn. 1989 Dec;24(6):655-62 [2514117.001]
  • (PMID = 16575511.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 23
  •  go-up   go-down


56. Yilmaz Y, Alahdab YO, Yonal O, Kurt R, Kedrah AE, Celikel CA, Ozdogan O, Duman D, Imeryuz N, Avsar E, Kalayci C: Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism; 2010 Sep;59(9):1327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis.
  • Recent evidence has suggested an association between microalbuminuria and ultrasound-diagnosed nonalcoholic fatty liver disease (NAFLD) in patients with diabetes and prediabetes.
  • We thus evaluated the relationships between microalbuminuria and liver histology in a hospital-based sample of 87 adults with biopsy-proven NAFLD from Turkey.
  • There were no differences in the prevalence of microalbuminuria in patients with definite nonalcoholic steatohepatitis, borderline nonalcoholic steatohepatitis, and simple fatty liver.
  • [MeSH-major] Albuminuria / complications. Fatty Liver / complications. Liver / pathology. Liver Cirrhosis / complications

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Metabolism. 2010 Sep;59(9):E5; author reply E6 [20417942.001]
  • (PMID = 20096896.001).
  • [ISSN] 1532-8600
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Jin HB, Gu ZY, Yu CH, Li YM: Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. Hepatobiliary Pancreat Dis Int; 2005 Aug;4(3):389-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients.
  • BACKGROUND: Nonalcoholic fatty liver disease (NAFLDéis a common chronic liver disease in China, of which diabetic fatty liver (DFLéaccounts for a large proportion in clinic.
  • DFL is a disease without specific clinical features and lacking of confirmatory laboratory tests, and the etiology of hepatic steatosis remains poorly understood.
  • The aim of this paper was to explore the clinical characteristics and to determine associated risk factors in type 2 diabetes patients with fatty liver.
  • CONCLUSIONS: Dyslipidemia, dysglycemia and elevation of liver enzyme can be seen more frequently in the DFL patients than in the NDFL patients.
  • [MeSH-major] Diabetes Mellitus, Type 2 / complications. Fatty Liver / blood. Fatty Liver / etiology
  • [MeSH-minor] Aged. Alanine Transaminase / blood. Blood Glucose / metabolism. Case-Control Studies. Cholesterol, HDL / blood. Enzymes / blood. Female. Humans. Lipids / blood. Liver / enzymology. Male. Middle Aged. Risk Factors. Triglycerides / blood


58. De Leeuw K, Woestenburg A, Verbeelen D: Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis. NDT Plus; 2008 Dec;1(6):412-413
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis.
  • But there has been ongoing concern about lanthanum accumulation in tissues, especially in liver.
  • We describe the case of a woman with pre-existing liver disease, who presented with acute liver failure after introduction of lanthanum carbonate to her treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S79-86 [15508107.001]
  • [Cites] Kidney Int. 2005 Dec;68(6):2809-13 [16316357.001]
  • [Cites] Kidney Int. 2005 Mar;67(3):1062-9 [15698446.001]
  • [Cites] Semin Dial. 2006 May-Jun;19(3):195-9 [16689967.001]
  • [Cites] CNS Drugs. 2005;19(3):185-92 [15740174.001]
  • (PMID = 28657006.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; chronic renal failure / lanthanum carbonate / liver disease / phosphor
  •  go-up   go-down


59. Wiegard C, Lohse AW: [Liver and rheumatism]. Z Rheumatol; 2005 Feb;64(1):26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver and rheumatism].
  • [Transliterated title] Leber und Rheuma.
  • There are multiple relations between rheumatic diseases and the liver, nevertheless the liver is extremely rare involved in rheumatic diseases.
  • "Elevated liver enzymes" are quite often found in patients who are under the medication with immunosuppressive drugs or/and non-steroidal antirheumatics.
  • The most frequent cause for "elevated liver enzymes" are toxic and allergic side effects of drugs; however, in rare cases it might be extremely helpful to examine, whether an independent liver disease exists.
  • Underlying liver diseases which might be associated with the rheumatic disorder or exist accidentally may change the therapeutic management of the patient.
  • If the liver disease present can cause the rheumatic disorder (e. g. virus-induced vasculitis, hemochromatosis), a specific hepatological therapy should precede the immunosuppression.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Antirheumatic Agents / therapeutic use. Liver Diseases / complications. Liver Diseases / diagnosis. Rheumatic Diseases / complications. Rheumatic Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Metab Brain Dis. 2004 Dec;19(3-4):357-81 [15554428.001]
  • [Cites] Semin Oncol. 1992 Oct;19(5):551-65 [1411653.001]
  • [Cites] Semin Arthritis Rheum. 1992 Jun;21(6):376-86 [1626283.001]
  • [Cites] Q J Med. 1968 Jan;37(145):171-82 [5657764.001]
  • [Cites] Hepatology. 1990 May;11(5):730-4 [2347546.001]
  • [Cites] Nature. 1969 Aug 2;223(5205):472-6 [4894426.001]
  • [Cites] Intern Med. 2004 Mar;43(3):258-62 [15098613.001]
  • [Cites] J Hepatol. 1998 Mar;28(3):525-6 [9551696.001]
  • [Cites] Clin Rheumatol. 2003 Sep;22(3):234-6 [14505218.001]
  • [Cites] QJM. 2003 Nov;96(11):787-91 [14566034.001]
  • [Cites] J Viral Hepat. 2003 Jul;10 (4):298-305 [12823597.001]
  • [Cites] J Rheumatol. 2001 Nov;28(11):2466-73 [11708420.001]
  • [Cites] Medicine (Baltimore). 1980 Sep;59(5):367-79 [7432153.001]
  • [Cites] Curr Opin Rheumatol. 2004 Jan;16(1):62-6 [14673391.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):631-5 [11394667.001]
  • [Cites] Lupus. 1993 Aug;2(4):275-9 [8268978.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3317-26 [12483738.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] Rheumatology (Oxford). 2002 Feb;41(2):176-9 [11886966.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2004 Oct;18(5):663-76 [15454125.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Aug;16(8):801-7 [15256984.001]
  • [Cites] Pediatr Dermatol. 2004 Sep-Oct;21(5):577-9 [15461767.001]
  • [Cites] Am J Pathol. 1978 Mar;90(3):619-32 [24342.001]
  • [Cites] Z Gastroenterol. 2003 Jun;41(6):517-22 [12806536.001]
  • (PMID = 15756497.001).
  • [ISSN] 0340-1855
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 28
  •  go-up   go-down


60. Chan SC, Lo CM, Ng KK, Fan ST: Alleviating the burden of small-for-size graft in right liver living donor liver transplantation through accumulation of experience. Am J Transplant; 2010 Apr;10(4):859-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alleviating the burden of small-for-size graft in right liver living donor liver transplantation through accumulation of experience.
  • The issue of small-for-size graft (SFSG) containing the middle hepatic vein in right liver living donor liver transplantation from 1996 to 2008 (n = 320) was studied.
  • Characteristics of donors, grafts and recipients were comparable between Era I (first 50 cases) and Era II (next 270 cases) except that the median model for end-stage liver disease (MELD) score was higher in Era I (29 vs. 24; p = 0.024).
  • The median graft to standard liver volume ratio (G/SLV) in Era I was 49.0% (range, 32.8-86.2%), versus 49.3% (range, 28.4-89.4%) in Era II (p = 0.498).
  • [MeSH-major] Liver Transplantation. Living Donors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148811.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Abboud G, Kaplowitz N: Drug-induced liver injury. Drug Saf; 2007;30(4):277-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced liver injury.
  • Drug-induced liver injury is a frequent cause of hepatic dysfunction.
  • Reliably establishing whether the liver disease was caused by a drug requires the exclusion of other plausible causes and the search for a clinical drug signature.
  • The drug signature consists of the pattern of liver test abnormality, the duration of latency to symptomatic presentation, the presence or absence of immune-mediated hypersensitivity and the response to drug withdrawal.
  • Determination of causality also includes an evaluation of individual susceptibility to drug-induced liver injury.
  • Components of the drug signature in conjunction with certain risk factors have been incorporated into formal scoring systems that are predictive of the likelihood of drug-induced liver injury.
  • Mitigating the potential for drug-induced liver injury is achieved by the identification of toxicity signals during clinical trials and the monitoring of liver tests in clinical practice.
  • There are three signals of liver toxicity in clinical trials: (i) a statistically significant doubling (or more) in the incidence of serum alanine aminotransferase (ALT) elevation >3 x the upper limit of normal (ULN);.
  • Monitoring of liver tests in clinical practice has shown unconvincing efficacy, but where a benefit-risk analysis would favour continued therapy, monthly monitoring may have some benefit compared with no monitoring at all.
  • With rare exception, treatment of drug-induced liver injury is principally supportive.
  • Drug toxicity is the most common cause of acute liver failure, defined as a prolonged prothrombin time (international normalised ratio > or =1.5) and any degree of mental alteration occurring <26 weeks after the onset of illness in a patient without pre-existing cirrhosis.
  • A patient who meets these criteria must be evaluated for liver transplantation.
  • The pathogenesis of drug-induced liver injury can be examined on the basis of the two principal patterns of injury.
  • [MeSH-major] Chemical and Drug Induced Liver Injury. Drug-Related Side Effects and Adverse Reactions. Liver Diseases / diagnosis
  • [MeSH-minor] Animals. Drug Monitoring / methods. Humans. Liver / drug effects. Liver / pathology. Liver / physiopathology. Liver Function Tests. Models, Biological. Pharmaceutical Preparations / administration & dosage. Risk Factors

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Res Toxicol. 2001 Feb;14 (2):175-81 [11258966.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1425-34 [12774022.001]
  • [Cites] Gastroenterology. 1997 Mar;112(3):923-34 [9041255.001]
  • [Cites] JAMA. 1999 Mar 17;281(11):1014-8 [10086436.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S44-8 [14986274.001]
  • [Cites] Chem Res Toxicol. 2001 Jun;14(6):694-701 [11409940.001]
  • [Cites] Am J Med. 2003 Mar;114(4):299-306 [12681458.001]
  • [Cites] Hepatology. 2004 May;39(5):1430-40 [15122773.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):916-7 [9518284.001]
  • [Cites] Anesth Analg. 2002 Feb;94(2):243-9, table of contents [11812677.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Sep 24;226(3):695-702 [8831677.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4333-40 [7722291.001]
  • [Cites] JAMA. 2002 May 1;287(17):2273-5 [11980528.001]
  • [Cites] Gut. 1989 Apr;30(4):515-9 [2714684.001]
  • [Cites] Clin Exp Allergy. 1998 Sep;28 Suppl 4:71-7 [9761038.001]
  • [Cites] Hepatology. 1999 Jan;29(1):1-4 [9862841.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1760-74 [15578514.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S83-9 [15758665.001]
  • [Cites] J Infect Dis. 2005 Oct 15;192(8):1381-6 [16170755.001]
  • [Cites] JAMA. 1994 Dec 21;272(23 ):1845-50 [7990219.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27432-40 [11369777.001]
  • [Cites] Clin Liver Dis. 2006 May;10 (2):207-17, vii [16971258.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):802-11 [9466975.001]
  • [Cites] Hepatology. 2006 Jun;43(6):1220-30 [16729305.001]
  • [Cites] J Clin Epidemiol. 1993 Nov;46(11):1331-6 [8229111.001]
  • [Cites] Hepatology. 2005 Dec;42(6):1364-72 [16317692.001]
  • [Cites] Chest. 2005 Jul;128(1):116-23 [16002924.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1170-9 [15486922.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Surg Res. 1998 Dec;80(2):252-8 [9878321.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):231-3 [16552791.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):e676-81 [16950959.001]
  • [Cites] Drug Metab Rev. 2004 May;36(2):301-12 [15237856.001]
  • [Cites] Chem Res Toxicol. 1998 Sep;11(9):969-88 [9760271.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Chem Res Toxicol. 2006 Feb;19(2):223-33 [16485898.001]
  • [Cites] Clin Pharmacol Ther. 2000 Apr;67(4):432-7 [10801254.001]
  • [Cites] J Hepatol. 1997;26 Suppl 1:23-30 [9138125.001]
  • [Cites] Dig Dis Sci. 1991 Sep;36(9):1223-8 [1716546.001]
  • [Cites] J Leukoc Biol. 1994 Mar;55(3):398-400 [7907127.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):493-503 [16859400.001]
  • [Cites] FASEB J. 2002 Aug;16(10 ):1227-36 [12153990.001]
  • [Cites] Gut. 1997 Oct;41(4):534-40 [9391255.001]
  • [Cites] Gastroenterology. 1990 Feb;98 (2):502-4 [2295408.001]
  • [Cites] Science. 2000 Feb 4;287(5454):860-4 [10657301.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):687-94 [16530510.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1603-12 [15185301.001]
  • [Cites] J Hepatol. 1997;26 Suppl 2:12-21 [9204405.001]
  • [Cites] Hepatology. 1992 Feb;15(2):244-51 [1735527.001]
  • [Cites] Science. 2001 Sep 7;293(5536):1829-32 [11546872.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):423-32 [11864614.001]
  • [Cites] Toxicol Pathol. 1996 Mar-Apr;24(2):181-9 [8992608.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1245-52 [10751350.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1587-91 [11075787.001]
  • [Cites] Immunol Rev. 2000 Apr;174:5-20 [10807503.001]
  • [Cites] Gastroenterology. 2000 Feb;118(2):422-30 [10648470.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6480-6 [10843705.001]
  • [Cites] Crit Rev Toxicol. 2005 Apr-May;35(4):325-61 [15989140.001]
  • [Cites] Hepatology. 2002 Aug;36(2):451-5 [12143055.001]
  • [Cites] Eur J Immunol. 2006 Apr;36(4):1028-38 [16552707.001]
  • [Cites] Drug Saf. 2001;24(7):483-90 [11444721.001]
  • [Cites] Annu Rev Immunol. 1994;12:991-1045 [8011301.001]
  • [Cites] Chem Res Toxicol. 1999 May;12(5):387-95 [10328748.001]
  • [Cites] Toxicol Sci. 2000 Apr;54(2):509-16 [10774834.001]
  • [Cites] Immunity. 2004 Oct;21(4):539-50 [15485631.001]
  • [Cites] Toxicology. 2001 Oct 5;167(1):73-81 [11557131.001]
  • [Cites] J Hepatol. 1997;26 Suppl 1:31-5 [9138126.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Apr 1;172(1):44-51 [11264022.001]
  • [Cites] Drug Saf. 2005;28(4):351-70 [15783243.001]
  • [Cites] Hepatology. 2000 Jan;31(1):201-6 [10613746.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Apr;61(2):135-43 [15726344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5498-503 [10792025.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):415-20 [16481451.001]
  • [Cites] Clin Pharmacol Ther. 2003 May;73(5):435-55 [12732844.001]
  • [Cites] Hepatology. 2002 Apr;35(4):883-9 [11915035.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1849-54 [7768392.001]
  • [Cites] Ann Intern Med. 2002 Dec 17;137(12):947-54 [12484709.001]
  • [Cites] Hepatology. 2005 Aug;42(2):481-9 [16025496.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):512-21 [16083708.001]
  • [Cites] Cell Death Differ. 1999 Jun;6(6):516-24 [10381654.001]
  • [Cites] Hepatology. 2001 Jan;33(1):123-30 [11124828.001]
  • [Cites] Hepatology. 2006 Mar;43(3):618-31 [16496329.001]
  • [Cites] Hepatology. 2003 Apr;37(4):924-30 [12668988.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):962-71 [10500080.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):921-30 [11015434.001]
  • [Cites] Hepatology. 1995 Sep;22(3):767-73 [7657281.001]
  • [Cites] Neurology. 2001 May 22;56(10 ):1405-9 [11376200.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):286-301 [8419252.001]
  • [Cites] Hepatology. 2005 May;41(5):1179-97 [15841455.001]
  • [Cites] Toxicol Appl Pharmacol. 1995 Jul;133(1):43-52 [7597709.001]
  • [Cites] Dig Dis. 1994 Jul-Aug;12(4):191-8 [7850998.001]
  • [Cites] Hepatology. 2004 Jul;40(1):10-5 [15239079.001]
  • [Cites] J Hepatol. 1990 Sep;11(2):272-6 [2254635.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):716-9 [8780577.001]
  • [Cites] Clin Liver Dis. 2003 May;7(2):351-67 [12879988.001]
  • [Cites] Hepatology. 2001 Nov;34(5):964-71 [11679967.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):39-47 [10728793.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24453-6 [11356822.001]
  • [Cites] J Hepatol. 1997;26 Suppl 2:37-42 [9204408.001]
  • [Cites] Chest. 1991 Feb;99(2):465-71 [1824929.001]
  • [Cites] Clin Liver Dis. 2000 Feb;4(1):73-96, vi [11232192.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1541-51 [9834283.001]
  • [Cites] Hepatology. 1998 Apr;27(4):1021-9 [9537442.001]
  • [Cites] Mol Pharmacol. 2001 Mar;59(3):627-35 [11179459.001]
  • [Cites] Clin Pharmacol Ther. 2001 Apr;69(4):223-31 [11309550.001]
  • [Cites] Immunol Rev. 2000 Apr;174:63-76 [10807507.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Ann Intern Med. 1984 Apr;100(4):495-9 [6230976.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1871-6 [9620920.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):489-99 [15931258.001]
  • [Cites] J Clin Epidemiol. 1993 Nov;46(11):1323-30 [8229110.001]
  • [Cites] Am J Cardiol. 2000 Jun 22;85(12A):15E-9E [10858489.001]
  • [Cites] J Exp Med. 1997 Apr 21;185(8):1481-6 [9126928.001]
  • (PMID = 17408305.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  • [Number-of-references] 126
  •  go-up   go-down


62. Rozga J: Liver support technology--an update. Xenotransplantation; 2006 Sep;13(5):380-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver support technology--an update.
  • BACKGROUND: Currently, there is no direct treatment for hepatic failure, and patients must receive a transplant or endure prolonged hospitalization, with significant morbidity and mortality.
  • Because of the scarcity of donor organs, liver support strategies are being developed with the aim of either supporting patients with borderline functional liver cell mass until an appropriate organ becomes available for transplantation or until their livers recover from injury.
  • RESULTS: Currently, a number of blood purification systems and devices utilizing viable liver cells are in various stages of clinical development.
  • These systems are able to remove toxins of hepatic failure, and their utility is limited by their inability to provide missing liver-specific functions.
  • In contrast, hepatocyte-based devices are able to provide whole liver functions, including detoxification, biosynthesis, and biotransformation.
  • Molecular adsorbent recycling system (MARS) blood detoxification system has been tested in thousands of patients, but additional well-conducted controlled studies are warranted to better define the role of MARS in the treatment of patients with acute hepatic failure and acute exacerbation of chronic liver disease.
  • HepatAssist was tested in a phase II/III controlled clinical trial that demonstrated safety and proof of concept for use of biological liver support systems to improve patient survival in acute hepatic failure.
  • CONCLUSIONS: Developing an effective liver assist technology has proven difficult, because of the complexity of liver functions that must be replaced, as well as heterogeneity of the patient population.
  • Non-biological systems may have a role in the treatment of specific forms of liver failure where the primary goal is to provide blood detoxification/purification.
  • Biological systems appear to be useful in treating liver failure where the primary objective is to provide whole liver functions which are impaired or lost.
  • It is suggested that there will be a role for hybrid liver support systems that offer liver cell therapy and various forms of blood purification (sorption, hemofiltration and diafiltration) to treat patients with specific forms of liver failure at various stages of their illness.
  • [MeSH-major] Liver Failure, Acute / therapy. Liver, Artificial
  • [MeSH-minor] Animals. Hemodiafiltration / methods. Hepatocytes / metabolism. Humans. Liver Transplantation. Renal Dialysis / methods. Sorption Detoxification / methods. Swine

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925661.001).
  • [ISSN] 0908-665X
  • [Journal-full-title] Xenotransplantation
  • [ISO-abbreviation] Xenotransplantation
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 67
  •  go-up   go-down


63. Machado MA, Makdissi FF, Surjan RC, Kappaz GT, Yamaguchi N: Two-stage laparoscopic liver resection for bilateral colorectal liver metastasis. Surg Endosc; 2010 Aug;24(8):2044-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-stage laparoscopic liver resection for bilateral colorectal liver metastasis.
  • BACKGROUND: Hepatectomy may prolong the survival of colorectal cancer patients with liver metastases.
  • Two-stage liver surgery is a valid option for the treatment of bilobar colorectal liver metastasis.
  • This video demonstrates technical aspects of a two-stage pure laparoscopic hepatectomy for bilateral liver metastasis.
  • To the authors' knowledge, this is the first description of a two-stage laparoscopic liver resection in the English literature.
  • METHODS: A 54-year-old man with right colon cancer and synchronous bilobar colorectal liver metastasis underwent laparoscopic right colon resection followed by oxaliplatin-based chemotherapy.
  • The patient then was referred for surgical treatment of liver metastasis.
  • Liver volumetry showed a small left liver remnant.
  • Surgical planning was for a totally laparoscopic two-stage liver resection.
  • The postoperative pathology showed high-grade liver steatosis.
  • After 4 weeks, the left liver had regenerated, and volumetry of left liver was 43%.
  • The line of liver transection was marked following the ischemic area.
  • Liver transection was accomplished with the Harmonic scalpel and an endoscopic stapling device.
  • The falciform ligament was fixed to maintain the left liver in its original anatomic position, avoiding hepatic vein kinking and outflow syndrome.
  • CONCLUSION: Two-stage liver resections can be performed safely using laparoscopy.
  • The intrahepatic Glissonian approach is a useful tool for pedicle control of the right liver, especially after previous dissection of the hilar plate.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy / methods. Laparoscopy. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Sep;246(3):385-92; discussion 392-4 [17717442.001]
  • [Cites] Br J Surg. 2005 May;92(5):592-5 [15779074.001]
  • [Cites] Ann Surg. 2008 Dec;248(6):994-1005 [19092344.001]
  • [Cites] Am J Surg. 2009 Jun;197(6):737-9 [18789420.001]
  • [Cites] Br J Surg. 1999 Jun;86(6):784-8 [10383579.001]
  • [Cites] Am J Surg. 2008 Oct;196(4):e38-42 [18614140.001]
  • [Cites] Am J Surg. 2009 Aug;198(2):173-7 [19268902.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2005 Jun;15(3):180-3 [15956908.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Jun;19(3):409-13 [19215213.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):918-20 [12912755.001]
  • [Cites] Arch Surg. 2008 Oct;143(10):978-82; discussion 982 [18936377.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51 [15570209.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):164-70 [12831938.001]
  • (PMID = 20108150.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Li X, Zhou XP, Guan YS, Wang YX: Magnetic resonance imaging of hepatocellular carcinoma induced by diethylnitrosamine in Sprague-Dawley rats. Hepatobiliary Pancreat Dis Int; 2005 Aug;4(3):427-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Diethylnitrosamine (DENA) is able to induce various benign and malignant liver lesions in rats with a high success rate and a low mortality rate.
  • It provides a more appropriate model that better simulates the various lesions occurring in humans than the usual model of tumor implantations.
  • The aim of the present study was to evaluate MRI liver examination in Sprague-Dawley (SD) rats as a routine method to detect hepatocellular carcinoma (HCC) nodules induced by DENA and to follow up their growth.
  • METHODS: Hepatic carcinogenesis was induced in 80 male SD rats using oral DENA solution.
  • All animals were imaged for liver tumor detection with a 1.5 Tesla magnet (Siemens Sonata, Erlangen, Germany) using correspondence scan parameters and a radio-frequency knee coil.
  • Hepatic tumors in 72 rats were confirmed macroscopically and 68 rats were detected by MRI till the 20th week.
  • CONCLUSIONS: The hepatic tumor induced by DENA provides a more representative range of tumors for imaging diagnosis and interventional treatment.
  • MRI is the best approach for scrutinizing pathological changes of rat livers in the period of observation.
  • [MeSH-major] Alkylating Agents. Diethylnitrosamine. Liver Neoplasms, Experimental / chemically induced. Liver Neoplasms, Experimental / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109530.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Alkylating Agents; 3IQ78TTX1A / Diethylnitrosamine
  •  go-up   go-down


65. Reuben A: Alcohol and the liver. Curr Opin Gastroenterol; 2006 May;22(3):263-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol and the liver.
  • PURPOSE OF REVIEW: To apprise the reader of advances in 2005 in the epidemiology, pathogenesis, prognosis and treatment of alcoholic liver disease.
  • Alcohol use has declined in developed countries, but the opposite is true elsewhere; alcoholic liver disease is a considerable burden worldwide.
  • RECENT FINDINGS: Genetic mechanisms for alcoholic liver disease are being discovered in addition to aggravating cofactors, such as hepatitis C, obesity and iron overload, and ameliorating ones, like coffee and tea drinking.
  • The involvement of the innate immune system and the mechanisms of apoptosis in alcoholic liver disease are better appreciated, especially the emerging role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
  • Steroid use and nutrition for alcoholic hepatitis are being refined, and the validity of the model for end-stage liver disease (MELD) score in predicting the outcome of alcoholic liver disease is upheld.
  • Recidivism after liver transplantation for alcoholic liver disease adversely impacts long-term survival.
  • SUMMARY: Inroads are being made into the genetics of alcoholic liver disease and new phenomena are being uncovered in its pathogenesis, but safe and effective therapies for both alcoholic hepatitis and alcoholic cirrhosis are still wanting.
  • [MeSH-major] Liver Diseases, Alcoholic / etiology. Liver Diseases, Alcoholic / physiopathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550041.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 140
  •  go-up   go-down


66. Bouchnak M, Souissi K, Ouragini H, Abbes Z, Douiri H, Maghrebi H: [Maternal benefit of postpartum corticosteroid therapy in patients with HELLP (hemolysis elevated liver enzymes low platelets count) syndrome]. Tunis Med; 2005 Aug;83(8):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Maternal benefit of postpartum corticosteroid therapy in patients with HELLP (hemolysis elevated liver enzymes low platelets count) syndrome].
  • [Transliterated title] Intérêt de la corticothérapie en post partum dans le HELLP (hemolysis elevated liver enzymes low platelets count) syndrome.
  • Our purpose was to assess the effects of corticotherapy prescribed after delivery on the kinetic of biological parameters of HELLP syndrome (hemolysis elevated liver enzymes low platelets count).
  • The kinetic of the hepatic cytolysis marker was not modified by corticotherapy.

  • Genetic Alliance. consumer health - HELLP syndrome.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238275.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Placebos; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


67. Wasmuth HE, Trautwein C: [Liver fibrosis : clinics, diagnostics and management]. Internist (Berl); 2010 Jan;51(1):14-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver fibrosis : clinics, diagnostics and management].
  • Liver fibrosis results from chronic liver damage and is characterized by scarring of the liver parenchyma.
  • Liver fibrosis can occur in all chronic liver diseases and shows progression towards liver cirrhosis in 20-40% of cases.
  • The clinical presentation of liver fibrosis is usually unspecific.
  • Therefore, most patients with liver fibrosis are identified by elevated liver enzymes during other medical examinations.
  • The gold standard for quantification of liver fibrosis is percutaneous liver biopsy, but non-invasive markers (e. g. serum markers, transient elastography) have recently been evaluated to identify individuals with significant fibrosis.
  • In case of fibrosis detection, medical therapies aim at stabilizing liver scarring or even at inducing the regression of fibrosis.
  • Primarily this is achieved by etiology specific therapies of chronic liver diseases (e. g. antiviral therapy, immunosuppressive therapy etc.).
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Liver Cirrhosis / diagnosis. Liver Cirrhosis / drug therapy

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2008 Sep;135(3):821-9 [18593587.001]
  • [Cites] Hepatology. 2007 Mar;45(3):569-78 [17326152.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):309-19, 319.e1-3 [19344719.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):1022 [12297856.001]
  • [Cites] N Engl J Med. 2001 Feb 8;344(6):418-23 [11172178.001]
  • [Cites] World J Gastroenterol. 2009 Mar 28;15(12):1409-14 [19322911.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1661-3 [17969048.001]
  • [Cites] Hepatology. 2003 Oct;38(4):859-68 [14512873.001]
  • [Cites] BMC Gastroenterol. 2007 Oct 15;7:40 [17937811.001]
  • [Cites] Hepatology. 2008 Aug;48(2):418-31 [18563841.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] J Hepatol. 2008 Apr;48(4):606-13 [18222014.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2297-307 [17135584.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1670-81 [18471546.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):598-607 [17692984.001]
  • [Cites] Hepatology. 2008 Mar;47(3):789-98 [18175357.001]
  • [Cites] J Hepatol. 2008 May;48(5):835-47 [18334275.001]
  • [Cites] Hepatology. 2007 Sep;46(3):912-21 [17705266.001]
  • [Cites] Hepatology. 2008 Feb;47(2):592-5 [18098325.001]
  • [Cites] Hepatology. 2006 Aug;44(2):472-7 [16871557.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):257-65 [12586290.001]
  • [Cites] N Engl J Med. 2008 Dec 4;359(23 ):2429-41 [19052125.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1704-13 [15578508.001]
  • (PMID = 19921111.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


68. Shih NN, Tsung JS, Yang AH, Tsou MH, Cheng TY: A unique pancreatic tumor with exclusive hepatocytic differentiation. Ann Clin Lab Sci; 2006;36(2):216-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique pancreatic tumor with exclusive hepatocytic differentiation.
  • Only 7 cases of pancreatic tumor with hepatocytic differentiation have been reported in the literature, including 6 cases of hepatoid carcinoma and one case of hepatoid adenoma.
  • Diagnosis of hepatoid carcinoma depends on recognition of characteristic histological features, supported by other evidence linked to hepatic lineage including alpha-fetoprotein production, positive immunoreactivity to liver synthesized proteins, and in situ hybridization detection of albumin mRNA.
  • We report a unique case of pancreatic tumor with exclusive hepatocytic differentiation.
  • In this tumor, we were unable to find a synchronous focus of carcinoma arising in pancreatic ducts, islet cells, or acinar cells, ruling out the possibility of its being hepatoid carcinoma.
  • Long term follow-up can help to determine whether this tumor is benign or malignant.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / analysis. Carcinoembryonic Antigen / analysis. Humans. Incidental Findings. Male

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682522.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


69. Greco LG, Tedeschi M, Stasolla S, Gentile A, Gentile A, Piscitelli D: Abdominal nodal localization of Castleman's disease: report of a case. Int J Surg; 2010;8(8):620-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Castleman's disease (CD) is a rare benign disorder that may grow in any area where lymphoid tissue is normally present but the most frequent site is mediastinum (67%); the abdomen is rarely affected by this pathology.
  • Diagnosis is difficult and the diagnostic certainty is obtained only by histological examination.
  • CONCLUSION: CD must be included in the differential diagnosis of retroperitoneal tumors even though the definitive diagnosis can only be achieved by histological and immunohistochemical examination.
  • [MeSH-major] Abdomen. Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / surgery
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Antibodies / blood. Diagnosis, Differential. Female. Herpesvirus 8, Human / immunology. Humans. Retroperitoneal Neoplasms / diagnosis. Weight Loss

  • Genetic Alliance. consumer health - Castleman's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20674810.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies
  •  go-up   go-down


70. Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C: Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg; 2009 Nov;250(5):738-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.
  • BACKGROUND/PURPOSE: Liver transplantation (LT) is the best theoretical treatment of hepatocellular carcinoma (HCC) fulfilling the Milan criteria (TNM stages 1-2).
  • However, LT is limited by organ availability and tumor progression on the waiting list.
  • Liver resection (LR) may represent an alternative in these patients.
  • PATIENTS: From 1990 to 2007, 274 patients underwent liver resection for HCC.
  • Ten were TNM stage 1 and 57 stage 2 and all had chronic liver disease.
  • After a mean follow-up of 4.8 years, 36 patients (54%) developed intrahepatic tumor recurrence.
  • Survival was not influenced by TNM stage 1 or 2, AFP level, tumor differentiation, or the presence microscopic vascular invasion.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatitis / complications. Hepatitis C / complications. Humans. Liver Cirrhosis, Alcoholic / complications. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate


71. Montalvo-Jave EE, Villegas-Alvarez F, Montalvo-Arenas CE, Peña-Sánchez J, Gutiérrez-Vega R, Piña E: Liver transplantation: some advances in liver cancer, live liver donation, and cell transplantation. A literature review. Rev Gastroenterol Mex; 2009 Oct-Dec;74(4):341-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation: some advances in liver cancer, live liver donation, and cell transplantation. A literature review.
  • Liver transplantation constitutes a constant challenge in finding viable options to maintain or recover an adequate function when faced with end-stage liver failure.
  • Critical review of the literature was conducted in specific topics on liver transplantation and development in Mexico.
  • We focused our review on medical and surgical topics such as liver procurement from a related living donor, liver transplantation options for patients with liver cancer, especially hepatocellular carcinoma and cholangiocarcinoma, as well as on cellular and molecular biology aspects, such as xenotransplantation and hepatocyte transplantation.
  • [MeSH-major] Cell Transplantation. Liver Neoplasms / surgery. Liver Transplantation. Tissue and Organ Procurement


72. Vander Borght S, Libbrecht L, Blokzijl H, Faber KN, Moshage H, Aerts R, Van Steenbergen W, Jansen PL, Desmet VJ, Roskams TA: Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol; 2005 Dec;207(4):471-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver.
  • Hepatocellular adenoma and focal nodular hyperplasia (FNH) are benign liver tumours.
  • The differential diagnosis of these lesions and of well- to moderately differentiated hepatocellular carcinomas is often difficult but is very important in view of their different treatment.
  • We therefore evaluated the expression and localization of hepatic transporters in hepatocellular adenomas, different types of FNH and well- to moderately differentiated hepatocellular carcinomas in non-cirrhotic liver and compared them with normal liver, using real-time RT-PCR and (semi-)quantitative immunohistochemistry.
  • The finding that each type of focal lesion in non-cirrhotic liver has a specific transporter expression pattern may be useful in the establishment of a correct diagnosis by imaging or on needle biopsy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Liver Neoplasms / diagnosis. Membrane Transport Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adult. Carcinoma, Hepatocellular / diagnosis. Diagnosis, Differential. Female. Focal Nodular Hyperplasia / diagnosis. Gene Expression. Humans. Immunoenzyme Techniques. Liver / metabolism. Male. Middle Aged. Multidrug Resistance-Associated Proteins / metabolism. Organic Anion Transport Polypeptide C / metabolism. Organic Anion Transporters, Sodium-Independent / metabolism. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland.
  • (PMID = 16161006.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Organic Anion Transport Polypeptide C; 0 / Organic Anion Transporters, Sodium-Independent; 0 / RNA, Neoplasm; 0 / SLCO1B3 protein, human; 0 / multidrug resistance-associated protein 3
  •  go-up   go-down


73. Chaplin A, Conrad DM, Tatlidil C, Jollimore J, Walsh N, Covert A, Pasternak S: Primary cutaneous PEComa. Am J Dermatopathol; 2010 May;32(3):310-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopic examination of the excisional specimen revealed a dermal tumor composed of nests of epithelioid cells exhibiting clear cytoplasm.
  • The tumor showed an infiltrative border.
  • Immunohistochemical evaluation revealed that the tumor cells were positive for HMB-45 and microftalmia associated transcription factor (MITF).
  • The tumor cells were negative for S-100 protein, alfa smooth muscle actin, HHF-35, and various cytokeratins.
  • Pecomas are rare, recently described mesenchymal tumors composed of perivascular epithelioid cells.
  • They constitute a spectrum of lesions in different organs including angiomyolipoma of the kidney and liver, sugar tumor of the lung, lymphangiomatosis, and lymphangiomyoma.
  • Follow-up data is limited but they appear to behave in a benign fashion.
  • We report an additional case with the goal of alerting dermatopathologists to this distinctive unusual neoplasm.
  • [MeSH-major] Perivascular Epithelioid Cell Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Biopsy. Desmin / analysis. Female. Humans. Leg. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor / analysis. Middle Aged. Neoplasm Proteins / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139753.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Desmin; 0 / MITF protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins
  •  go-up   go-down


74. Kandpal H, Sharma R, Madhusudhan KS, Kapoor KS: Respiratory-triggered versus breath-hold diffusion-weighted MRI of liver lesions: comparison of image quality and apparent diffusion coefficient values. AJR Am J Roentgenol; 2009 Apr;192(4):915-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory-triggered versus breath-hold diffusion-weighted MRI of liver lesions: comparison of image quality and apparent diffusion coefficient values.
  • OBJECTIVE: The purpose of our study was to compare respiratory-triggered and breath-hold diffusion-weighted liver MRI and to assess the agreement in the apparent diffusion co-efficient (ADC) values between the two sequences.
  • MATERIALS AND METHODS: Forty-eight patients (27 men, 21 women; mean age, 45.2 years) with focal liver lesions underwent respiratory-triggered and breath-hold diffusion-weighted MRI (DWI) in addition to routine MRI.
  • A total of 92 lesions (maximum of three lesions per patient; 37 benign, 55 malignant) were evaluated.
  • Signal-to-noise ratio (SNR) of the liver, contrast-to-noise ratio (CNR), and relative contrast ratio of the lesions were measured in each DWI sequence and were statistically compared using the Mann-Whitney U test.
  • The ADC values of normal liver and each category of liver lesions in the two sequences were compared for agreement using Pearson's coefficient and reliability analysis scale.
  • RESULTS: The SNR of the normal liver was significantly better on respiratory-triggered DWI than on breath-hold DWI.
  • The ADC values of liver and focal lesions measured by the two techniques showed good agreement.
  • The SDs of the ADC values of normal liver were similar in the two sequences.
  • CONCLUSION: Respiratory-triggered DWI should be preferred over breath-hold DWI for the evaluation of focal liver lesions because it provides better image quality and SNR without any compromise in the calculated ADC values.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Liver Neoplasms / diagnosis. Respiratory-Gated Imaging Techniques / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304695.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


75. Sang XT, DU SD, Mao YL, Lu X, Yang ZY, Huo L, Zhong SX, Huang JF: [The values of (11)C-acetate and (18)F-fluorodeoxyglucose positron emission tomography in diagnosis of indefinite liver masses]. Zhonghua Yi Xue Za Zhi; 2007 Nov 27;87(44):3122-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The values of (11)C-acetate and (18)F-fluorodeoxyglucose positron emission tomography in diagnosis of indefinite liver masses].
  • OBJECTIVE: To evaluate the values of the two tracers of positron emission tomography (PET) in the liver masses not definitely diagnosed by routine examinations.
  • METHODS: Fifteen patients with liver masses of indefinite diagnosis after serum tests and common imaging examinations underwent PET with both (11)C-acetate and (18)F-fluorodeoxyglucose (FDG).
  • RESULTS: Pathological examination showed that 13 of the 15 patients were confirmed as malignant liver lesions and the other 2 as benign.
  • Within the 13 malignant liver lesions, (11)C-acetate-PET suggested malignancy in 10 cases, and benignancy in 3 cases.
  • In the two benign cases, both (11)C-acetate-PET and (18)F-FDG-PET showed one malignant liver lesion and one benign liver lesion. (11)C-acetate-PET showed a high sensitivity (100%) for the well-differentiated tumors, and (18)F-FDG-PET showed a high sensitivity for the poorly-differentiated tumors.
  • CONCLUSION: The diagnostic accuracy for liver lesions may be improved by the two tracers of PET when the lesions can not be definitely diagnosed by routine examinations and at the same time when the patients are able to afford two PET examinations.
  • They may also imply the cell-differentiation of the liver masses, and be helpful for selecting the treatment means for the patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods
  • [MeSH-minor] Acetates. Adult. Aged. Carbon Radioisotopes. Female. Humans. Liver / pathology. Liver / radionuclide imaging. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269870.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Acetates; 0 / Carbon Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


76. Bueno J, Escartín A, Balsells J, Margarit C: Intraoperative flow measurement of native liver and allograft during orthotopic liver transplantation in children. Transplant Proc; 2007 Sep;39(7):2278-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative flow measurement of native liver and allograft during orthotopic liver transplantation in children.
  • Hepatic hemodynamic changes during liver transplantation (OLT) in children have not yet been studied.
  • We measured intraoperative portal vein flow (PVF) and hepatic arterial flow (HAF) (mL/min) in 53 children and 58 grafts during OLT.
  • In the native liver, PVF and HAF are similar; after transplantation they return to the physiological situation.
  • Among the 8 (14%) portal vein thromboses, PVF was lower in both the native liver and the graft than in the no thrombosis group (P < .05).
  • [MeSH-major] Liver Circulation. Liver Transplantation. Monitoring, Intraoperative
  • [MeSH-minor] Blood Flow Velocity. Child. Hepatic Artery / physiology. Humans. Portal Vein / physiology. Thrombosis / diagnosis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889162.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Ikeda M, Hasegawa K, Sano K, Imamura H, Beck Y, Sugawara Y, Kokudo N, Makuuchi M: The vessel sealing system (LigaSure) in hepatic resection: a randomized controlled trial. Ann Surg; 2009 Aug;250(2):199-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The vessel sealing system (LigaSure) in hepatic resection: a randomized controlled trial.
  • OBJECTIVE: The aim of this trial was to verify the new surgical device (the LigaSure vessels sealing system) decrease liver transection time.
  • SUMMARY BACKGROUND DATA: Among the major goals in hepatic resection are minimization of the operation time and of the blood loss.
  • Preliminary reports have suggested that the vessel sealing system might decrease the liver transection time, which is directly associated with the amount of blood loss.
  • METHODS: Patients who were scheduled to undergo hepatic resection at the Tokyo University Hospital were assigned, by the minimization method, to either use of the new vessel sealing system (VS group) or the conventional clamp crushing method (CC group) for liver transection.
  • The primary end point was the liver transection time, and the secondary endpoints were the amount of blood loss during the entire operation and during liver transection, length of hospital stay, postoperative liver function, and the incidence of various adverse events.
  • RESULTS: From February to December in 2006, a total of 165 patients underwent liver resection for some benign or malignant disease of the liver.
  • The median liver transection time in the VS group was 57 minutes (range: 11-127), similar to that in the CC group (56 [range: 9-269] min, P = 0.64), while there was no difference in the transection speed between the 2 groups (1.16 [0.15-2.26] cm/min vs. 1.10 [0.15-2.66] cm/min, P = 0.95).
  • The amount of blood loss and blood loss per transection area during liver transaction in the VS group was also similar to that in the CC group (median: 315 [25-2415] mL vs. 315 [10-1700] mL; P = 0.80) and (5.04 [1.01-44.2] mL/cm vs. 4.36 [0.15-50.5] mL/cm; P = 0.14), respectively.
  • CONCLUSIONS: This randomized controlled trial showed that while the vessel sealing system was safe, its use was not associated with any significant decrease of the operation time or blood loss during liver transaction as compared with that of the clamp crushing method.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Carcinoma / surgery. Hemostasis, Surgical / instrumentation. Hepatectomy / adverse effects. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2009 Aug;250(2):204-5 [19638900.001]
  • (PMID = 19638927.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Song CH, Chen LM, Zhang LX: [Analysis of the result of 409 cases with liver cirrhosis and severe hepatitis by using the model for end-stage liver disease]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun;21(2):168-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the result of 409 cases with liver cirrhosis and severe hepatitis by using the model for end-stage liver disease].
  • OBJECTIVE: To analyze the influence of the model for end-stage liver disease (MELD) results in 409 cases with liver cirrhosis and severe hepatitis and compare with Child-Pugh scoring system.
  • METHODS: The data of 409 patients with liver cirrhosis and severe hepatitis were collected and analyzed by using the Child-Pugh and MELD scoring systems, and Chiss statistical software was applied.
  • CONCLUSION: The changes in total serum bilirubin and creatinine can influence the result significantly, not the INR, and a better way to predict the prognosis of severe liver disease may be application of MELD combined with clinical experience.
  • [MeSH-major] Hepatitis / diagnosis. Liver Cirrhosis / diagnosis. Liver Failure / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653326.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] AYI8EX34EU / Creatinine; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


79. Morgan K, Uyuni A, Nandgiri G, Mao L, Castaneda L, Kathirvel E, French SW, Morgan TR: Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol; 2008 Sep;20(9):843-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
  • OBJECTIVE: To determine whether expression of transcription factors and lipogenic enzymes is altered in liver and adipose tissue of mice with obesity, insulin resistance, and nonalcoholic fatty liver disease.
  • MEASUREMENTS: Liver injury was evaluated by histology and serum aminotransferase levels.
  • RESULTS: HF mice weighed more, had insulin resistance, hepatic steatosis, and focal pericellular hepatic fibrosis.
  • Hepatic expression of sterol regulatory element-binding protein-1c, carbohydrate response element-binding protein, liver X receptor-alpha, acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS) decreased during fasting in SF and HF mice; however, FAS expression and protein content were higher in the liver of fasted HF mice than of fasted SF mice.
  • In adipose tissue, expression of sterol response element-binding protein-1c, carbohydrate response element-binding protein, liver X receptor-alpha, peroxisome proliferator-activated receptor-gamma, ACC, and FAS decreased with fasting in mice fed SF, but not in HF mice.
  • During fasting, hepatic FAS expression and protein content are increased in HF mice.
  • De-novo lipogenesis may persist in liver and adipose tissue during fasting in obesity/nonalcoholic fatty liver disease.
  • [MeSH-major] Fatty Liver / genetics. Gene Expression Regulation. Lipogenesis / genetics. Liver / metabolism. Obesity / genetics

  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794597.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Grant] United States / PHS HHS / / P50-011999-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Transcription Factors; 0 / Triglycerides; EC 2.3.1.85 / Fatty Acid Synthases; EC 6.4.1.2 / Acetyl-CoA Carboxylase
  •  go-up   go-down


80. Schwab SA, Bautz W, Uder M, Kuefner MA: [The von Meyenburg complex]. Rontgenpraxis; 2008;56(6):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Der von Meyenburg Komplex.
  • The von Meyenburg complex (VMC) describes bile duct hamartomas and presents a rare, benign incidental finding in liver imaging.
  • Computed tomography (CT) revealed multiple hypodense lesions throughout the liver, primary suggesting recurrent Hodgkin's disease.
  • Previous CT-examinations, which were obtained at a later date, showed those Lesions in identical distribution and morphology over the years, leading to diagnosis of multiple bile duct hamartomas (VMC).
  • Making imaging-based diagnosis of VMC including ultrasound, CT and magnetic resonance imaging is a challenging task for the radiologist.
  • [MeSH-major] Bile Duct Neoplasms / radiography. Hamartoma / radiography. Liver / radiography. Neoplasms, Multiple Primary / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Follow-Up Studies. Hodgkin Disease / radiography. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294869.001).
  • [ISSN] 0035-7820
  • [Journal-full-title] Röntgenpraxis; Zeitschrift für radiologische Technik
  • [ISO-abbreviation] Rontgenpraxis
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


81. Humar A, Horn K, Kalis A, Glessing B, Payne WD, Lake J: Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant; 2005 Feb;5(2):399-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence?
  • Concern exists that partial liver transplants (either a living donor [LD] or deceased donor [DD] in hepatitis C virus (HCV)-positive recipients may be associated with an increased risk for recurrence.
  • From 1999 to 2003, at our institution, 51 HCV-positive recipients underwent liver transplants: 32 whole-liver (WL) transplants, 12 LD transplants and 7 DD split transplants.
  • Donor characteristics differed in that WL donors were older, and LD livers had lower ischemic times.
  • With a mean follow-up of 28.3 months, 46 (90%) recipients are alive: three died from HCV recurrent liver disease and two from tumor recurrence.
  • Liver regeneration does not seem to affect hepatitis C recurrence as much, perhaps, as factors such as DD status, donor age and cold ischemic time.
  • [MeSH-major] Hepatitis C / surgery. Liver Regeneration. Liver Transplantation. Living Donors


82. Norén B, Lundberg P, Ressner M, Wirell S, Almer S, Smedby O: Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease. Eur Radiol; 2005 Jan;15(1):148-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease.
  • Phosphorus-31 NMR spectroscopy using slice selection (DRESS) was used to investigate the absolute concentrations of metabolites in the human liver.
  • Nine patients with histopathologically proven diffuse liver disease and 12 healthy individuals were examined in a 1.5-T MR scanner (GE Signa LX Echospeed plus).
  • (1) determination of optimal depth for the in vivo measurements, (2) mapping the detection coil characteristics, (3) calculation of selected slice and liver volume ratios using simple segmentation procedures and (4) spectral analysis in the time domain.
  • Absolute concentration measurements of phosphorus metabolites in the liver are feasible using a slice selective sequence, and the technique demonstrates significant differences between patients and healthy subjects.
  • [MeSH-major] Liver Diseases / metabolism. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Hydrogen-Ion Concentration. Liver Function Tests. Male. Middle Aged. Phosphorus Isotopes. Sensitivity and Specificity. Signal Processing, Computer-Assisted. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 1989 Nov;12(2):282-9 [2559292.001]
  • [Cites] Prog Biophys Mol Biol. 1996;65(1-2):45-81 [9029941.001]
  • [Cites] J Biol Chem. 1987 Jan 5;262(1):35-7 [3793728.001]
  • [Cites] Liver. 1997 Aug;17(4):198-209 [9298490.001]
  • [Cites] Anal Biochem. 1990 Dec;191(2):193-222 [2085167.001]
  • [Cites] Hepatology. 1995 Feb;21(2):417-27 [7843715.001]
  • [Cites] MAGMA. 2002 Mar;14(1):30-8 [11796250.001]
  • [Cites] Magn Reson Imaging. 1992;10(6):949-56 [1461092.001]
  • [Cites] NMR Biomed. 1996 Jun;9(4):141-55 [9015801.001]
  • [Cites] NMR Biomed. 1996 May;9(3):93-104 [8892395.001]
  • [Cites] Dig Dis Sci. 1994 Jan;39(1):33-8 [8281864.001]
  • [Cites] MAGMA. 2001 Aug;13(1):40-6 [11410395.001]
  • [Cites] Clin Sci (Lond). 1990 Jan;78(1):33-8 [2153493.001]
  • [Cites] Magn Reson Med. 1994 Oct;32(4):453-8 [7997109.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):953-8 [2069850.001]
  • [Cites] JAMA. 1999 Nov 3;282(17):1659-64 [10553793.001]
  • [Cites] NMR Biomed. 1999 Dec;12(8):535-44 [10668046.001]
  • [Cites] Hepatology. 2003 Apr;37(4):788-94 [12668971.001]
  • [Cites] Magn Reson Imaging. 2000 Feb;18(2):181-7 [10722978.001]
  • [Cites] Magn Reson Med. 1989 Oct;12(1):145-50 [2558272.001]
  • [Cites] NMR Biomed. 1992 May-Jun;5(3):114-20 [1322688.001]
  • [Cites] Acta Radiol. 1998 May;39(3):309-14 [9571950.001]
  • [Cites] NMR Biomed. 1993 Mar-Apr;6(2):168-72 [8499248.001]
  • [Cites] Biochim Biophys Acta. 1993 Nov 25;1225(1):71-7 [8241291.001]
  • [Cites] Metabolism. 1996 Sep;45(9):1059-61 [8781290.001]
  • [Cites] Gut. 1996 Jul;39(1):141-6 [8881826.001]
  • [Cites] Biochemistry. 1968 Nov;7(11):4030-4 [4972613.001]
  • [Cites] NMR Biomed. 1993 May-Jun;6(3):215-24 [8347456.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):776-88 [7875480.001]
  • [Cites] Scand J Clin Lab Invest. 1975 May;35(3):245-51 [1153922.001]
  • [Cites] Biochim Biophys Acta. 1995 Oct 17;1272(2):113-8 [7548234.001]
  • [Cites] Biochim Biophys Acta. 1978 Dec 4;514(1):1-8 [718902.001]
  • [Cites] Gut. 1990 Apr;31(4):463-7 [2338275.001]
  • [Cites] Magn Reson Med. 1988 Jan;6(1):92-8 [3352510.001]
  • [Cites] Radiology. 1989 Nov;173(2):393-400 [2798871.001]
  • [Cites] Am J Physiol. 1994 Feb;266(2 Pt 2):R638-45 [8141425.001]
  • [Cites] Magn Reson Imaging. 1998;16(2):205-11 [9508277.001]
  • [Cites] J Magn Reson Imaging. 1992 Mar-Apr;2(2):183-90 [1562769.001]
  • [Cites] Hepatology. 1995 Feb;21(2):443-9 [7843719.001]
  • [Cites] Magn Reson Med. 1994 Oct;32(4):447-52 [7997108.001]
  • [Cites] Gut. 2002 Jan;50(1):118-22 [11772978.001]
  • (PMID = 15351899.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phosphorus Isotopes
  •  go-up   go-down


83. Attallah AM, Shiha GE, Ismail H, Mansy SE, El-Sherbiny R, El-Dosoky I: Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection. Clin Biochem; 2009 Apr;42(6):455-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
  • OBJECTIVES: Hepatitis C virus (HCV) is a major aetiological agent of chronic hepatitis and it leads to the development of liver cirrhosis and hepatocellular carcinoma (HCC).
  • The significances of p53 protein and anti-p53 antibodies levels in HCV genotype IV infected patients with different liver pathology were evaluated.
  • DESIGN AND METHODS: Immunostaining and western blot based on monospecific anti-p53 antibody were used for the identification of p53 protein in liver tissues and serum samples.
  • RESULTS: Mild and diffuse p53 cytoplasmic immunostaining was found in liver tissues of patients with liver fibrosis [F1-F3] and liver cirrhosis [F4] in comparison with strong and diffuse p53 cytoplasmic immunostaining in patients with HCC.
  • The target p53 protein was identified in sera of patients with liver fibrosis, liver cirrhosis and HCC at 53-kDa.
  • The detection rate of serum p53 protein increases significantly (p<0.05) with the progression of the liver pathology.
  • However, a significant difference (p<0.05) was only shown between serum p53 protein level of HCC patients and those of other liver pathology.
  • In contrast, anti-p53 IgG antibodies positive rates showed only a significant decrease (p<0.05) in HCC in comparison with liver cirrhosis.
  • CONCLUSIONS: The serum and cytoplasmic p53 protein expressions were more pronounced in patients with HCC more than liver cirrhosis, and in liver cirrhosis more than liver fibrosis.
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Hepatitis C, Chronic / blood. Liver / metabolism. Liver Cirrhosis / blood. Liver Neoplasms / blood. Tumor Suppressor Protein p53

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19063876.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Immunoglobulin G; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


84. Li H, Lu Q, Dong LH, Xue H, Zhou HY, Yang HJ: [Expression of fatty acid binding protein in human breast cancer tissues]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Apr;23(4):312-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: adipocyte-FABP (A-FABP), heart or muscle FABP (H-FABP), brain-FABP (B-FABP), epidermis or psoriasis FABP (E-FABP), liver FABP (L-FABP), intestinal FABP (I-FABP) and gastro-FABP (G-FABP) expression in 35 ductal infiltrating carcinoma and 16 fibroadenoma of breast were detected by RT-PCR, immunohistochemical staining and Western blot analysis, respectively.
  • RESULTS: E-, L-, and H-FABP were up regulated significantly in ductal infiltrating carcinoma when compared with those in benign tissue (P<0.05).
  • However, there were not significant difference in A-, B-, G-, and I-FABP expression between ductal infiltrating carcinoma and benign tissue (P>0.05).
  • Interestingly, H-FABP was not only found in benign tissues but in some of ductal infiltrating carcinomas, furthermore, H-FABP level was elevated in malignant tissue, compared with that in benign tissue.
  • [MeSH-major] Breast Neoplasms / metabolism. Fatty Acid-Binding Proteins / genetics. Fatty Acid-Binding Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17428383.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Fatty Acid-Binding Proteins
  •  go-up   go-down


85. Stutchfield BM, Rashid S, Forbes SJ, Wigmore SJ: Practical barriers to delivering autologous bone marrow stem cell therapy as an adjunct to liver resection. Stem Cells Dev; 2010 Feb;19(2):155-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical barriers to delivering autologous bone marrow stem cell therapy as an adjunct to liver resection.
  • Liver resection has been associated with significant morbidity and mortality due to hepatic dysfunction or hepatic failure in the postoperative period.
  • Autologous bone marrow stem cell (BMSC) therapy may offer the potential to enhance hepatic regeneration in this setting, perhaps increasing the safety of the procedure.
  • Preclinical models and initial translational studies have suggested that autologous BMSC administration can facilitate hepatic regeneration following both acute and chronic liver disease.
  • While translational studies have begun in chronic hepatic disease, translation to hepatic surgical indications has been limited.
  • This review explores the practical barriers currently restricting the delivery of autologous stem cell therapies to enhance hepatic regeneration following liver resection including selection of cell type, cell isolation, therapy delivery, trial design, and assessment of efficacy.
  • [MeSH-major] Bone Marrow Transplantation / methods. Liver Diseases / physiopathology. Liver Diseases / surgery. Liver Regeneration

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954303.001).
  • [ISSN] 1557-8534
  • [Journal-full-title] Stem cells and development
  • [ISO-abbreviation] Stem Cells Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


86. Barshes NR, Lee TC, Udell IW, O'mahoney CA, Karpen SJ, Carter BA, Goss JA: The pediatric end-stage liver disease (PELD) model as a predictor of survival benefit and posttransplant survival in pediatric liver transplant recipients. Liver Transpl; 2006 Mar;12(3):475-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pediatric end-stage liver disease (PELD) model as a predictor of survival benefit and posttransplant survival in pediatric liver transplant recipients.
  • The pediatric end-stage liver disease (PELD) model accurately estimates 90-day waitlist mortality for pediatric liver transplant candidates, but it has been unclear if PELD can identify patients who will derive survival benefit from undergoing liver transplantation (LT), if it correlates with posttransplant survival, or if it can identify patients for whom LT would be futile.
  • Complete data were available for 1,247 patients: 53% were listed as Status 1 at the time of orthotopic liver transplantation (OLT), while the remaining 47% had PELD scores.
  • In conclusion, pediatric patients with a PELD score of 17+ derive survival benefit early after LT, and increasing PELD scores are associated with increasing transplant benefit after liver transplantation.
  • [MeSH-major] Algorithms. Cause of Death. Liver Failure / mortality. Liver Transplantation / mortality. Postoperative Complications / mortality. Tissue and Organ Procurement

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 AASLD
  • (PMID = 16498644.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Sumida W, Kaneko K, Tainaka T, Ono Y, Kiuchi T, Ando H: Liver transplantation for multiple liver metastases from solid pseudopapillary tumor of the pancreas. J Pediatr Surg; 2007 Dec;42(12):e27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for multiple liver metastases from solid pseudopapillary tumor of the pancreas.
  • Solid pseudopapillary tumor (SPT) of the pancreas usually shows a benign clinical course.
  • We report the case of a 14-year-old girl with SPT of the pancreas and unresectable synchronous liver metastasis who underwent successful living donor liver transplantation.
  • This is the first report on transplantation to relieve liver metastasis of SPT.
  • [MeSH-major] Carcinoma, Papillary / secondary. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Liver Transplantation / methods. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Female. Follow-Up Studies. Graft Survival. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / surgery. Humans. Immunohistochemistry. Neoplasm Staging. Risk Assessment. Treatment Outcome


88. Hervé J, Cunha AS, Liu B, Valogne Y, Longuet M, Boisgard R, Brégerie O, Roux J, Guettier C, Calès P, Tavitian B, Samuel D, Clerc J, Bréchot C, Faivre J: Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther; 2008 Sep;19(9):915-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter.
  • The hepatocarcinoma-intestine-pancreas (HIP) gene, also called pancreatitis-associated protein-1 (PAP1) or Reg IIIalpha, is activated in most human hepatocellular carcinomas (HCCs) but not in normal liver, which suggests that HIP regulatory sequence could be used as efficient liver tumor-specific promoters to express a therapeutic polynucleotide in liver cancer.
  • For this purpose, we constructed a recombinant rat HIP-NIS adenoviral vector (AdrHIP-NIS), and evaluated its performance as a mediator of selective radioiodide uptake in tumor hepatocytes.
  • Western blot, immunofluorescence, and iodide uptake assays were performed in AdrHIP-NIS-infected primary hepatocytes and transformed hepatic and nonhepatic cells.
  • Nuclear imaging, tissue counting and immunohistochemistry were performed in normal and HCC-bearing Wistar rats infected with AdrHIP-NIS intratumorally or via the hepatic artery.
  • In AdrHIP-NIS-infected transformed hepatic cells, functional NIS was strongly expressed, as in cells infected with a cytomegalovirus-NIS vector.
  • In rats bearing multinodular HCC, AdrHIP-NIS triggered functional NIS expression that was preferential in tumor hepatocytes.
  • This study has identified the rHIP regulatory sequence as a potent liver tumor-specific promoter for the transfer of therapeutic genes, and AdrHIP-NIS-mediated (131)I therapy as a valuable option for the treatment of multinodular HCC.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Lectins, C-Type / genetics. Liver Neoplasms, Experimental / radiotherapy. Liver Neoplasms, Experimental / therapy
  • [MeSH-minor] Adenoviridae / genetics. Animals. Base Sequence. Cell Line. Cell Line, Tumor. DNA, Recombinant / genetics. Dogs. Female. Gene Expression. Gene Transfer Techniques. Genetic Vectors. Humans. Iodine Radioisotopes / administration & dosage. Iodine Radioisotopes / therapeutic use. Male. Promoter Regions, Genetic. Rats. Rats, Wistar. Symporters / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759560.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Recombinant; 0 / Iodine Radioisotopes; 0 / Lectins, C-Type; 0 / Symporters; 0 / pancreatitis-associated protein; 0 / sodium-iodide symporter
  •  go-up   go-down


89. Modlin IM, Shapiro MD, Kidd M: An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg; 2005 Jan;29(1):92-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of rare carcinoid tumors: clarifying these clinical conundrums.
  • Carcinoid tumors are distinct neuroendocrine neoplasms with characteristic histological, clinical, and biological properties.
  • Though commonly associated with the gastrointestinal tract and bronchopulmonary system, a substantial number of these tumors originate in less common anatomical sites and can range from indolent, unrecognized entities to highly active, metastatic secretory tumors.
  • The authors reviewed 13,715 carcinoid tumors identified by three consecutive registries of the National Cancer Institute (NCI) from 1950 to 1999, focusing on the anatomic sites accounting for less than one percent of all carcinoids.
  • In addition, data from the world's literature published on carcinoid tumors within these particular anatomic locations were then analyzed with respect to incidence, clinical presentation, symptoms, diagnostic evaluation, microscopic and immunohistochemical findings, treatment strategies, and prognosis.
  • The primary organs in which carcinoids are most commonly mistaken for some of the more conspicuous endemic tumors include the esophagus, pancreas, liver, biliary tract, gallbladder, and Meckel's diverticulum, as well as within the pelvic and otolaryngeal organs and the breast.
  • Tumors with the worst prognosis were those that involved the pancreas (37.5%: 5-year survival) and those in the cervix (12-33%: 3-year survival).
  • The diminution of the likelihood of inadvertently neglecting these often benign, indolent neoplasms that are well known to metastasize if unaddressed would represent an important advance.
  • Familiarity with such unusual sites of origin will facilitate appropriate recognition and characterization of such tumors, allowing for timely intervention.
  • [MeSH-major] Carcinoid Tumor / surgery
  • [MeSH-minor] Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Breast Neoplasms / surgery. Esophageal Neoplasms / surgery. Female. Gallbladder Neoplasms / surgery. Humans. Laryngeal Neoplasms / surgery. Liver Neoplasms / surgery. Male. Ovarian Neoplasms / surgery. Pancreatic Neoplasms / surgery. Testicular Neoplasms / surgery. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1996 Mar-Apr;53(2):153-8 [8604242.001]
  • [Cites] Ultrastruct Pathol. 1993 Jan-Feb;17(1):115-21 [8427027.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1241-9 [10189128.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):229-35 [7546678.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1705-13 [6383596.001]
  • [Cites] Patol Pol. 1978 Apr-Jun;29(2):237-40 [704186.001]
  • [Cites] N Y State J Med. 1969 May 15;69(10):1337-9 [5255420.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1334-9 [11688471.001]
  • [Cites] Lancet. 1954 Nov 6;267(6845):951 [13213086.001]
  • [Cites] Z Gastroenterol. 1974 Sep;12 Suppl(0):377-84 [4418379.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):897-909 [1707237.001]
  • [Cites] Intern Med. 1996 Dec;35(12 ):953-6 [9030993.001]
  • [Cites] J Urol. 1977 Nov;118(5):777-82 [916100.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2189-95 [10521965.001]
  • [Cites] J Gastroenterol. 1995 Jun;30(3):398-402 [7647908.001]
  • [Cites] Cancer. 1975 Aug;36(2):404-18 [1157010.001]
  • [Cites] Digestion. 1997;58(4):410-4 [9324172.001]
  • [Cites] J Am Coll Surg. 1994 Feb;178(2):187-211 [8173736.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1580-8 [8156484.001]
  • [Cites] Ital J Surg Sci. 1986;16(4):249-53 [3557930.001]
  • [Cites] Gynecol Oncol. 1996 May;61(2):259-65 [8626144.001]
  • [Cites] Thorax. 1989 Jul;44(7):594-6 [2672408.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1476-81 [9118026.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1726-32 [7688660.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):93-5 [7679854.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1109-16 [8758239.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4209-13 [10566674.001]
  • [Cites] Eur J Nucl Med. 1995 Mar;22(3):281-3 [7789401.001]
  • [Cites] Pathol Annu. 1979;14 Pt 1:273-91 [42037.001]
  • [Cites] Diagn Cytopathol. 1989;5(2):217-20 [2776604.001]
  • [Cites] J Gastroenterol. 1999 Feb;34(1):123-7 [10204622.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Jul 25;99:442-4 [14430796.001]
  • [Cites] J Intern Med. 1995 Sep;238(3):281-8 [7673859.001]
  • [Cites] Z Gastroenterol. 1998 Mar;36(3):233-8 [9577907.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Sep;64(3):413-21 [5054879.001]
  • [Cites] J Magn Reson Imaging. 2000 Feb;11(2):141-8 [10713946.001]
  • [Cites] J Urol. 1954 Nov;72(5):892-4 [13212896.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1119-24 [12201876.001]
  • [Cites] Int J Urol. 2001 Sep;8(9):522-4 [11683977.001]
  • [Cites] Histopathology. 1987 Jan;11(1):53-62 [2881873.001]
  • [Cites] J Am Osteopath Assoc. 2000 Jul;100(7):432-4 [10943090.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Hepatogastroenterology. 1998 Sep-Oct;45(23):1462-7 [9840084.001]
  • [Cites] Surgery. 1998 Nov;124(5):831-8 [9823395.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Jul;99(7 Pt 1):547-52 [2164339.001]
  • [Cites] J Laryngol Otol. 1983 Nov;97(11):1073-80 [6644166.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Acta Oncol. 1993;32(2):225-9 [7686765.001]
  • [Cites] Heart. 1998 Dec;80(6):623-6 [10065036.001]
  • [Cites] Jpn J Clin Oncol. 1989 Dec;19(4):397-401 [2607641.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1959-65 [10570419.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1501-10 [11075851.001]
  • [Cites] Ear Nose Throat J. 2002 Jan;81(1):40-3 [11816388.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1211-8 [2302669.001]
  • [Cites] Ann R Coll Surg Engl. 1959 Dec;25(5):277-97 [19310224.001]
  • [Cites] J Clin Gastroenterol. 1996 Jul;23(1):60-2 [8835904.001]
  • [Cites] Arch Otolaryngol. 1969 Jul;90(1):64-7 [5785991.001]
  • [Cites] Can J Surg. 1999 Feb;42(1):59-63 [10071590.001]
  • [Cites] Acta Cytol. 1990 Mar-Apr;34(2):119-24 [2181800.001]
  • [Cites] Ann Surg Oncol. 1998 Apr-May;5(3):261-4 [9607629.001]
  • [Cites] Diagn Cytopathol. 2001 Sep;25(3):168-71 [11536440.001]
  • [Cites] Pathol Int. 1999 Apr;49(4):318-24 [10365851.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:159-69 [12381551.001]
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):589-96 [1587179.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):609-12 [8631405.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):23-32 [14687136.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Arch Anat Pathol (Paris). 1964 Sep;12:200-3 [14228034.001]
  • [Cites] Am J Clin Pathol. 1980 Jun;73(6):816-23 [6156597.001]
  • (PMID = 15599742.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


90. Lordan JT, Worthington TR, Quiney N, Fawcett W, Karanjia ND: Early postoperative outcomes following hepatic resection for benign liver disease in 79 consecutive patients. HPB (Oxford); 2009 Jun;11(4):321-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early postoperative outcomes following hepatic resection for benign liver disease in 79 consecutive patients.
  • BACKGROUND: Liver resection is an accepted treatment modality for malignant disease of the liver.
  • However, because of its potential morbidity and mortality, the practice of liver resection in benign disease is more controversial.
  • This study was designed to assess the early outcomes of 79 consecutive liver resections for benign disease over a 12-year period and compare these with early outcomes of 390 consecutive liver resections for metastatic colorectal cancer (MCRC) during the same period.
  • METHODS: Consecutive liver resections were carried out in a single hepatopancreatobiliary (HPB) centre between 1996 and 2008.
  • RESULTS: There was no difference in median age between the benign group vs. the MCRC group (P = 0.181).
  • However, there was a significant trend towards a lower ASA grade in the benign group (P < 0.001).
  • Morbidity rates were 8.9% in the benign group and 20.5% in the MCRC group (P = 0.002).
  • The rate of serious complications was 1.3% in the benign group compared with 4.4% in the MCRC group (P = 0.041).
  • There were no postoperative deaths in the benign group and eight (2%) in the MCRC group (P = 0.004).
  • CONCLUSIONS: Liver resection for benign liver tumours can be undertaken with a mortality rate approaching zero and minimal morbidity in specialist HPB units.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):302-6 [18328668.001]
  • [Cites] J Am Coll Surg. 2000 Jul;191(1):38-46 [10898182.001]
  • [Cites] Am J Surg. 2007 Jan;193(1):5-9 [17188079.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1192-201 [16983740.001]
  • [Cites] Int J Clin Oncol. 2005 Apr;10(2):86-96 [15864693.001]
  • [Cites] BMC Surg. 2005;5:5 [15774004.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):13-8 [7740799.001]
  • [Cites] Ann Surg. 1988 Aug;208(2):190-5 [2840865.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] Arch Surg. 2001 Sep;136(9):1033-8 [11529826.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):808-13 [11412249.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • (PMID = 19718359.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2727085
  • [Keywords] NOTNLM ; benign liver disease / liver resection
  •  go-up   go-down


91. Ritchie AH, Williscroft DM: Elevated liver enzymes as a predictor of liver injury in stable blunt abdominal trauma patients: case report and systematic review of the literature. Can J Rural Med; 2006;11(4):283-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated liver enzymes as a predictor of liver injury in stable blunt abdominal trauma patients: case report and systematic review of the literature.
  • Liver injury secondary to blunt abdominal trauma is a well-defined entity in emergency medicine.
  • A challenge exists in the diagnosis of liver trauma in the stable, wellappearing patient with a history of blunt abdominal trauma.
  • In centres lacking advanced diagnostic modalities an elevation in hepatic transaminases may provide guidance for the rural emergency physician in seeking further imaging and/or surgical consultation.
  • There appears to be a direct relationship between blunt liver trauma and elevation in liver transaminases.
  • [MeSH-major] Abdominal Injuries / blood. Liver / injuries. Transaminases / blood. Wounds, Nonpenetrating / diagnosis
  • [MeSH-minor] Adult. Humans. Liver Function Tests. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054829.001).
  • [ISSN] 1203-7796
  • [Journal-full-title] Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la médecine rurale : le journal officiel de la Société de médecine rurale du Canada
  • [ISO-abbreviation] Can J Rural Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] EC 2.6.1.- / Transaminases
  • [Number-of-references] 27
  •  go-up   go-down


92. Barreiros AP, Post F, Hoppe-Lotichius M, Linke RP, Vahl CF, Schäfers HJ, Galle PR, Otto G: Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl; 2010 Mar;16(3):314-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience.
  • Liver transplantation (LT) is the only curative option for patients with familial amyloid polyneuropathy (FAP) at present.
  • Seven patients received a pacemaker prior to LT, and because of impairment of mechanical cardiac function, 4 combined heart-liver transplants were performed, 1 simultaneously and 3 sequentially.
  • Cardiac symptoms occurred predominantly in patients with non-Val30Met mutations and prompted combined heart-liver transplantation in 4 patients.
  • Combined heart-liver transplantation should be considered in patients with restrictive cardiomyopathy.
  • [MeSH-major] Amyloid Neuropathies, Familial / surgery. Heart Transplantation. Liver Transplantation


93. Popescu I, Ciurea S, Romanescu D, Boros M: Isolated resection of the caudate lobe: indications, technique and results. Hepatogastroenterology; 2008 May-Jun;55(84):831-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This paper reports a series of 24 isolated caudate lobe resections (ICLR), performed for 13 benign tumors (10 hemangiomas, 2 focal nodular hyperplasias, 1 adenoma) and 11 malignant tumors (3 hepatocarcinomas, 1 peripheral cholangiocarcinoma and 7 metastatic - 5 colorectal carcinomas, 1 breast carcinoma, 1 adrenal carcinoma).
  • Klatskin tumors were excluded.
  • RESULTS: Complications occurred in 7 cases (3 bile leaks, 3 abdominal fluid collections and one liver failure leading to death).
  • From the 10 patients with malignant tumors who survived the operation, 7 developed recurrences: 2 intrahepatic, 1 retroperitoneal, 4 systemic.
  • CONCLUSIONS: ICLR is a difficult operation, especially with malignant tumors.
  • Total vascular exclusion of the liver is routinely recommended in high dorsal resection.
  • Malignant tumors located in the caudate lobe have a poor prognosis; local and, especially, distant metastases are frequent.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adenoma, Liver Cell / mortality. Adenoma, Liver Cell / pathology. Adenoma, Liver Cell / surgery. Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adult. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Female. Focal Nodular Hyperplasia / mortality. Focal Nodular Hyperplasia / pathology. Focal Nodular Hyperplasia / surgery. Hemangioma / mortality. Hemangioma / pathology. Hemangioma / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Postoperative Complications / mortality. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705277.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


94. Lau WY, Lai EC: Hepatic resection for colorectal liver metastases. Singapore Med J; 2007 Jul;48(7):635-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for colorectal liver metastases.
  • INTRODUCTION: Nearly 50 percent of patients who have colorectal carcinoma will develop liver metastases, which is frequently the cause of death.
  • Liver resection is the only curative treatment for patients with colorectal metastases confined to the liver.
  • However, liver resection can be performed in only ten percent of patients.
  • A strategy to improve resectability and outcome of patients with colorectal liver metastases is needed.
  • METHODS: The progress and outcome of patients, who had colorectal liver metastases and underwent liver resection in a tertiary surgical centre between January 1998 and December 2002, were retrospectively studied.
  • RESULTS: During the five-year study period, 42 patients with colorectal liver metastasis underwent hepatic resection.
  • 36 patients received primary liver resection.
  • Six patients with initially unresectable disease received salvage surgery after tumour downstaging with systemic chemotherapy.
  • Five of the 42 patients needed repeat liver resection for recurrent colorectal liver metastases.
  • The five-year survival rate with salvage surgery after tumour downstaging was 34 percent, and the corresponding figure, after repeat liver resection, for recurrent liver metastases was 27 percent.
  • CONCLUSION: Hepatic resection for colorectal metastases confined to the liver resulted in reasonably good long-term survival, with acceptably low operative mortality and morbidity.
  • Our results were compatible with the international standard of liver resection for colorectal liver metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609825.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


95. Patterson SA, Khalil HI, Panicek DM: MRI evaluation of small hepatic lesions in women with breast cancer. AJR Am J Roentgenol; 2006 Aug;187(2):307-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI evaluation of small hepatic lesions in women with breast cancer.
  • OBJECTIVE: The purpose of this study was to assess the utility of MRI in differentiating benign and malignant causes of hepatic lesions deemed too small to characterize on CT in women with breast cancer.
  • MATERIALS AND METHODS: A list of all women with breast cancer diagnosed between January 2000 and June 2003 was cross-referenced with radiologic and medical records to identify patients who had undergone MRI of the liver and who had had a hepatic lesion too small to characterize reported on previous CT performed after the diagnosis of breast cancer.
  • The cause reported at MRI for each hepatic lesion too small to characterize seen on CT was recorded as benign, malignant, indeterminate, or no lesion seen on MRI.
  • RESULTS: Seventy-six (1.4%) of 5,440 women underwent MRI that included the liver.
  • In 38 (50%) of the women a hepatic lesion too small to characterize was found on CT performed before MRI.
  • The reported MRI diagnoses of hepatic lesions too small to characterize on CT included benign lesions (n = 22 women), lesions that remained indeterminate (n = 11 women), no lesion seen on MRI corresponding to the site of a lesion too small to characterize on CT (n = 8 women), and metastatic lesions (n = 2 women).
  • Four women had more than one reported type of hepatic lesion.
  • Subsequent findings of imaging, biopsy, or both performed on eight of 11 women with indeterminate lesions supported benign diagnoses in all eight women.
  • CONCLUSION: In women with newly diagnosed breast cancer and no definite liver metastasis on initial CT, immediate further evaluation of hepatic lesions too small to characterize with MRI offers only marginal benefit.
  • [MeSH-major] Breast Neoplasms / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies


96. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC: Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol; 2008 Jun;19(6):1146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases.
  • BACKGROUND: The benefit of surgical resection of liver metastases from gastric cancer has not been well established.
  • The aim of this study was to evaluate the rationale for hepatic resection in patients with hepatic metastases from gastric cancer.
  • METHODS: Among 10 259 patients diagnosed with gastric adenocarcinoma in the Yonsei University Health System from 1995 to 2005, we reviewed the records of 58 patients with liver-only metastases from gastric cancer who underwent gastric resection regardless of hepatic surgery.
  • RESULTS: The overall 1-year, 3-year, and 5-year survival rates of 41 patients who underwent hepatic resection with curative intent were 75.3%, 31.7%, and 20.8%, respectively, and three patients survived >7 years.
  • The number of liver metastasis (solitary or multiple) was a marginally significant prognostic factor for survival.
  • CONCLUSIONS: Surgery for liver metastases arising from gastric adenocarcinoma is reasonable if complete resection seems feasible after careful preoperative staging, even if complete resection is not actually achieved.
  • Hepatic resection should be considered as an option for gastric cancer patients with hepatic metastases.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304963.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


97. Steurer W: [Liver transplantation]. Praxis (Bern 1994); 2006 Sep 20;95(38):1465-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplantation].
  • Liver transplantation has developed as standard therapy for end-stage liver disease and fulminant hepatic failure with excellent results.
  • The application of new techniques including split liver and living donor liver transplantation (LDLT) has only marginally increased the total number of liver transplants.
  • [MeSH-major] Liver Diseases / surgery. Liver Failure / surgery. Liver Neoplasms / surgery. Liver Transplantation


98. Iimuro Y, Brenner DA: Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res; 2008 Feb;25(2):249-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase gene delivery for liver fibrosis.
  • The resolution of advanced liver fibrosis has been recently recognized to be possible, if the causative stimuli are successfully removed.
  • However, whether complete resolution from cirrhosis, the end stage of liver fibrosis, can be achieved is still questionable.
  • Delivery of interstitial collagenases, such as matrix metalloproteinase (MMP)-1, in the liver could be an attractive strategy to treat advanced hepatic fibrosis from the view point that the imbalance between too few interstitial collagenases and too many of their inhibitors is the main obstacle to the resolution from fibrosis.
  • Remodeling of hepatic extracellular matrix by delivered interstitial collagenases also facilitates the disappearance of activated hepatic stellate cells, the main matrix-producing cells in the liver, and promotes the proliferation of hepatocytes.
  • This review will focus on the impact of the gene delivery of MMPs for the treatment of advanced liver fibrosis while discussing other current therapeutic strategies for liver fibrosis, and on the need for the development of a safe and effective delivery system of MMPs.
  • [MeSH-major] Genetic Therapy. Liver Cirrhosis / therapy. Matrix Metalloproteinases / genetics

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2004 Nov;40(5):1106-15 [15389776.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1151-9 [15389867.001]
  • [Cites] Am J Med. 1970 Nov;49:707-21 [4924592.001]
  • [Cites] N Engl J Med. 1988 Jun 30;318(26):1709-13 [3287167.001]
  • [Cites] Exp Pathol. 1988;34(4):229-36 [2853079.001]
  • [Cites] Gastroenterology. 1990 Jan;98(1):175-84 [2293576.001]
  • [Cites] J Clin Invest. 1989 Dec;84(6):1786-93 [2592560.001]
  • [Cites] Cell Mol Biol. 1990;36(2):131-53 [2165861.001]
  • [Cites] Hepatology. 1991 Feb;13(2):282-8 [1995439.001]
  • [Cites] J Clin Invest. 1992 Jul;90(1):282-7 [1634616.001]
  • [Cites] Hepatology. 1992 Oct;16(4):1014-21 [1398481.001]
  • [Cites] J Hepatol. 1992 Jul;15(3):336-44 [1447500.001]
  • [Cites] Semin Cell Biol. 1993 Jun;4(3):189-201 [7688595.001]
  • [Cites] Clin Chim Acta. 1993 Sep 17;218(1):47-58 [8299219.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):528-37 [8129038.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5858-69 [8065319.001]
  • [Cites] Virchows Arch. 1994;424(1):25-31 [7981900.001]
  • [Cites] J Biochem. 1995 Sep;118(3):643-9 [8690730.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):821-31 [8608892.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1847-53 [8964410.001]
  • [Cites] J Hepatol. 1996 Aug;25(2):200-5 [8878782.001]
  • [Cites] J Hepatol. 1996 Feb;24(2):238-45 [8907579.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):G116-23 [9038884.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1297-306 [9098016.001]
  • [Cites] Alcohol Clin Exp Res. 1997 Apr;21(2):375-9 [9113278.001]
  • [Cites] Gut. 1997 Jan;40(1):133-8 [9155591.001]
  • [Cites] J Hepatol. 1997 Sep;27(3):554-61 [9314134.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1069-73 [9322499.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1265-72 [9358752.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1530-7 [9397994.001]
  • [Cites] Gastroenterology. 1998 Jan;114(1):139-52 [9428228.001]
  • [Cites] Hepatology. 1998 Mar;27(3):720-6 [9500700.001]
  • [Cites] J Hepatol. 1998 Apr;28(4):615-21 [9566830.001]
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):538-49 [9691091.001]
  • [Cites] Hepatology. 1998 Dec;28(6):1525-31 [9828216.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1895-902 [9846979.001]
  • [Cites] Dig Dis Sci. 1998 Dec;43(12):2573-6 [9881484.001]
  • [Cites] J Hepatol. 2006 Sep;45(3):429-38 [16846660.001]
  • [Cites] Hepatology. 2007 Jan;45(1):213-22 [17187438.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11069-76 [11796725.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1525-8 [11984538.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):291-300 [12105857.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):739-45 [12174389.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):850-60 [12297832.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1647-52 [12457277.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):445-58 [12557150.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):504-20 [12557155.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8083-90 [12502711.001]
  • [Cites] J Hepatol. 2003 Apr;38(4):468-75 [12663239.001]
  • [Cites] Liver Transpl. 2003 Apr;9(4):331-8 [12682882.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):378-86 [9922319.001]
  • [Cites] Nat Med. 1999 Feb;5(2):226-30 [9930873.001]
  • [Cites] Hepatology. 1999 Oct;30(4):944-50 [10498646.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1304-11 [15565662.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):56-65 [15630444.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):108-20 [15633128.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G907-13 [15618280.001]
  • [Cites] Annu Rev Biochem. 2005;74:711-38 [15952901.001]
  • [Cites] FASEB J. 2006 Mar;20(3):444-54 [16507762.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1807-21 [16697743.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12719-24 [10535989.001]
  • [Cites] J Hepatol. 1999 Dec;31(6):1053-61 [10604579.001]
  • [Cites] J Hepatol. 1999 Dec;31(6):1120-30 [10604588.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2247-50 [10644669.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):32-8 [10728792.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1149-56 [10833490.001]
  • [Cites] J Hepatol. 2000 May;32(5):762-70 [10845663.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G245-9 [10915630.001]
  • [Cites] Arch Pathol Lab Med. 2000 Nov;124(11):1599-607 [11079009.001]
  • [Cites] Mol Ther. 2000 Dec;2(6):545-51 [11124055.001]
  • [Cites] N Engl J Med. 2001 Feb 8;344(6):418-23 [11172178.001]
  • [Cites] Curr Top Pathol. 1999;93:205-18 [10339913.001]
  • [Cites] Gut. 2001 Apr;48(4):548-57 [11247901.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1784-800 [11375959.001]
  • [Cites] J Hepatol. 2001 May;34(5):764-7 [11434626.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):148-55 [11438504.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28274-80 [11346654.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):685-98 [11522753.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):745-50 [11584371.001]
  • [Cites] Semin Liver Dis. 2001 Aug;21(3):437-51 [11586471.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):392-8 [11592601.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40591-8 [11509553.001]
  • [Cites] J Hepatol. 2001 Oct;35(4):474-81 [11682031.001]
  • [Cites] Clin Liver Dis. 2001 Nov;5(4):1073-90 [11685796.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(3):CD002148 [11687017.001]
  • [Cites] Front Biosci. 2002 Feb 1;7:d496-503 [11815289.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):178-91 [12851882.001]
  • [Cites] Br J Pharmacol. 2003 Jul;139(6):1085-94 [12871826.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Sep;15(9):951-7 [12923366.001]
  • [Cites] Hepatology. 2003 Oct;38(4):859-68 [14512873.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1849-58 [14578185.001]
  • [Cites] Tissue Eng. 2003 Dec;9(6):1289-99 [14674437.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):955-63 [15057733.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1122-33; discussion 949 [15057751.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1646-54 [15084697.001]
  • [Cites] Hepatology. 2004 May;39(5):1390-7 [15122768.001]
  • [Cites] BMC Gastroenterol. 2003 Oct 18;3:29 [14565855.001]
  • [Cites] Lab Invest. 2004 Jun;84(6):766-77 [15077122.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1795-808 [15188175.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):235-41 [15288472.001]
  • [Cites] Hepatology. 1999 Mar;29(3):858-67 [10051490.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2345-9 [10051644.001]
  • (PMID = 17577645.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 105
  • [Other-IDs] NLM/ PMC2245995
  •  go-up   go-down


99. Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, Morteza A, Nakhjavani M: Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Metab Syndr; 2010;2:65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound.
  • BACKGROUND: Despite ongoing findings on the relationship between elevated levels of alanine and aspartate aminotransferases (ALT and AST) and metabolic syndrome (MetS), this association in diabetic patients without a known cause for liver enzymes elevation other than diabetes, per se, remains unclear.
  • In this study, we aimed to assess the relationship between circulating liver enzymes and MetS in a relatively large sample of patients with diabetes.
  • Patients with ultrasonographic signs of fatty liver disease were not included.
  • CONCLUSION: In diabetic patients without ultrasonographic evidence of fatty liver, elevated aminotransferases are independently associated with MetS.
  • Despite negative ultrasound results in diabetic patients with MetS, the serum level of liver aminotransferases may be elevated and should be more thoroughly monitored.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21047423.001).
  • [ISSN] 1758-5996
  • [Journal-full-title] Diabetology & metabolic syndrome
  • [ISO-abbreviation] Diabetol Metab Syndr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2987914
  •  go-up   go-down


100. Cho SW, Marsh JW, Steel J, Holloway SE, Heckman JT, Ochoa ER, Geller DA, Gamblin TC: Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol; 2008 Oct;15(10):2795-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatocellular adenoma (HA) is a rare benign tumor of the liver.
  • [MeSH-major] Adenoma, Liver Cell / surgery. Hepatectomy. Laparoscopy. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18696154.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD 049109
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down






Advertisement